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Abstract 
 
Bone is one of the few organs that retains the potential for regeneration in adult 
life, as it possesses the ability to heal and to remodel. However, in several clinical 
settings bone is not able to heal by itself and further treatment is needed, such as in: 
bone fusion, reconstruction of a shattered bones, filling of bone defects caused by 
cysts or tumors, and stimulation of bone growth to help anchor an artificial joint or other 
implant. For most of these injuries, available treatments are still inadequate. Therefore, 
new strategies need to be considered.  
In view of this evidence, in this thesis a bone tissue engineering strategy, based 
on an injectable system in combination with mesenchymal stem cells (MSCs) and 
endothelial cells (ECs), was developed. The proposed system could potentially act as a 
bone filler to stimulate the repair and to enhance the bone function. 
As a starting point, it was investigated if a synergistic coculture system of MSCs 
with ECs could affect the number and state of differentiation of harvested MSCs. ECs 
have been previously shown to induce osteogenic differentiation in vitro and in vivo, 
when in direct contact with bone marrow stromal cells. However, in contrast with 
previously published reports on the interrelationship between these cell types, the 
present investigation was carried out for longer times, namely 3 weeks instead of 1 to 6 
days, and different ratios of both cell types were considered. Additionally, several 
media were tested and the osteogenic commitment of MSCs in a non-osteogenic 
medium, in the presence of ECs, was carefully analyzed. Collectively, it was 
demonstrated that, by coculturing MSCs with human umbilical vein endothelial cells 
(HUVECs), osteogenic differentiation was promoted (and even enhanced, depending 
on the relative cell ratios used), and MSCs proliferation was significantly increased as 
well. Hence, ECs appear to not only modulate MSC phenotype but also their 
proliferation rate.  
As a strategy to develop an injectable system able to deliver MSCs in a clinical 
setting they were immobilized within microspheres of alginate modified with the 
arginine-glycine-aspartic acid (RGD) peptide sequence. This hydrophilic polymeric 
network provided a 3D support for MSCs. Immobilized cells showed metabolic activity 
with a sustained viability, short cell extensions and, when induced, they were able to 
differentiate into the osteogenic lineage.  
Since bone is a highly vascularized tissue the stimulation of vascularization is a 
 x 
requirement of paramount importance in bone regeneration strategies. ECs play a key 
role in this process since they constitute the lining of blood vessels, and bone cells 
have been previously shown to influence ECs by secreting for instance vascular 
endothelial growth factor (VEGF), which is essential in angiogenesis. Therefore, the 
ability of MSCs immobilized within RGD-alginate microspheres to influence neighboring 
ECs was also investigated. MSCs produced VEGF that diffused through the hydrogel 
network into the surrounding medium, enhancing the ability of neighboring ECs to form 
tube-like structures in a reconstituted basement membrane (Matrigel).  
An alternative way to promote angiogenesis consists in promoting the in vitro 
prevascularization of a biomaterial. Cell-based therapies offer an attractive approach 
for tissue revascularization. However, and despite the pressing clinical needs for 
effective revascularization strategies, the successful immobilization of viable vascular 
cells within 3D matrices has been difficult to achieve. The in vitro potential of RGD-
alginate hydrogel to immobilized and deliver HUVECs was evaluated. HUVECs were 
able to proliferate and maintained a higher viability for at least 48h post-immobilization 
within the alginate matrix. Additionally, entrapped cells were able to create a 3D 
organization into cellular networks and, when put in contact with Matrigel, they 
migrated out of the RGD-matrix. Moreover, since this biomaterial was prepared from 
soluble precursors that promote its crosslinking in situ, this strategy was shown to 
support the in vitro formation of cellular networks by migrating cells and also to allow 
delivery of ECs at the injury site by minimally invasive methods. Overall, the potential 
of injectable alginate hydrogels as an in situ gel forming delivery systems for vascular 
cells was demonstrated. 
In summary, this thesis was focused on the need to enhance vascularization in 
bone regeneration strategies and its main findings are based in the close relationship 
between osteoprogenitor cells and endothelial cells, namely: i) ECs enhance MSCs 
differentiation and proliferation; ii) immobilized MSCs within RGD-modified alginate 
stimulate tube-like structures formation by ECs; iii) RGD-alginate provides an adequate 
3D environment to support ECs adhesion, survival, migration and organization. 
Moreover, the obtained results demonstrate that RGD-modified alginate hydrogel is a 
good candidate for minimally invasive bone tissue regeneration strategies, suitable to 
immobilize and deliver bone and endothelial cells. 
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Resumo 
 
O osso é um dos poucos órgãos que conserva potencial de regeneração na 
idade adulta graças à sua capacidade de cicatrização e remodelação. Em certas 
condições clínicas, porém, o osso é incapaz de cicatrizar por si próprio, exigindo um 
tratamento auxiliar adequado. São disso exemplo a fusão óssea, a reconstrução de 
ossos planos, o preenchimento de defeitos causados por quistos ou tumores e a 
estimulação do crescimento ósseo para facilitar a ancoragem de articulações artificiais 
ou outros implantes. Os tratamentos disponíveis para a maioria destas lesões 
continuam a ser inadequados, razão pela qual novas estratégias devem der 
equacionadas. 
Considerando estas evidências, a presente tese procurou desenvolver uma 
estratégia de engenharia de tecidos do osso baseada num sistema injectável em 
combinação com células estaminais mesenquimais (MSCs) e endoteliais (ECs). 
Actuando como um material de preenchimento, o sistema proposto pode 
potencialmente estimular a reparação do osso, incrementando também a função do 
mesmo. 
Como ponto de partida avaliou-se se um sistema sinergético de co-cultura de 
MSCs com ECs pode influenciar o número e estado de diferenciação das primeiras. 
Ensaios anteriores têm demonstrado que ECs induzem a diferenciação osteogénica in 
vitro e in vivo, quando em contacto directo com células estromais de medula óssea. 
No entanto, e contrariamente aos estudos publicados acerca da inter-relação entre os 
referidos tipos celulares, a corrente investigação foi realizada durante períodos de 
tempo mais alargados (3 semanas em detrimento de 1 a 6 dias), tendo ainda 
contemplado diferentes proporções de ambos os tipos celulares em análise. Em 
paralelo, diferentes meios de cultura foram testados e o comprometimento 
osteogénico de MSCs na presença de ECs num meio não-osteogénico 
detalhadamente analisado. De uma forma geral, foi demonstrado que co-cultivando 
MSCs com células endoteliais de veia umbilical humana (HUVECs) a diferenciação 
osteogénica é promovida (ou até melhorada dependendo das proporções relativas de 
células usadas), sendo ainda a proliferação de MSCs significativamente aumentada. 
Assim, as ECs parecem não só modular o fenótipo das MSCs mas também a sua taxa 
de proliferação. 
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Com o intuito de desenvolver um sistema injectável capaz de fornecer MSCs 
em cenários clínicos, estas células foram imobilizadas em microesferas de alginato 
modificado com a sequência peptídica arginina-glicina-aspartato (RGD). A rede 
polimérica hidrofílica assim constituída proporcionou um suporte 3D para as MSCs. As 
células imobilizadas mostraram uma actividade metabólica com viabilidade 
sustentada, extensões celulares curtas e, quando induzidas, capacidade de 
diferenciação na linhagem osteogénica. 
Sendo o osso um tecido altamente vascularizado, estimular a vascularização é 
um requisito de capital importância em estratégias de regeneração óssea. As ECs 
desempenham um papel crucial neste processo, uma vez que são parte constituinte 
da parede interna dos vasos sanguíneos. Por outro lado, a influência das células do 
osso nas ECs foi previamente demonstrada mediante a secreção de, por exemplo, 
factor de crescimento endotelial vascular (VEGF), elemento essencial na angiogénese. 
Por conseguinte, a possibilidade de MSCs imobilizadas em microesferas de alginato 
modificado com RGD influenciarem ECs vizinhas foi igualmente aferida. Nas nossas 
condições experimentais, as MSCs produziram VEGF que, ao difundir-se pela rede de 
hidrogel até ao meio circundante, incrementou a capacidade das ECs vizinhas 
formarem estruturas tubulares numa membrana basal reconstituída (Matrigel). 
 Uma forma alternativa de potenciar a angiogénese consiste em promover in 
vitro a pré-vascularização do biomaterial. As terapias baseadas em células constituem 
uma abordagem atractiva para a revascularização de tecidos. No entanto, e apesar da 
crescente urgência clínica em sistemas de revascularização profícuos, a imobilização 
eficiente de células vasculares viáveis em matrizes tridimensionais tem sido difícil de 
alcançar. Neste contexto, o potencial do hidrogel de alginato modificado com RGD 
imobilizar e fornecer HUVECs foi avaliado. As HUVECs foram capazes de proliferar e 
manter uma elevada viabilidade durante pelo menos 48h após imobilização na matriz 
de alginato. Cumulativamente, as células aprisionadas conseguiram criar redes 
celulares com organização tridimensional, tendo ainda migrado para o exterior da 
matriz RGD quando colocadas em contacto com o Matrigel. Para além disso, dado 
que este biomaterial foi preparado a partir de componentes precursores solúveis que 
determinam o seu crosslinking in situ, a estratégia seguida revelou sustentar a 
formação in vitro de redes celulares por células migrantes, permitindo ainda a 
aplicação de ECs no local da lesão através de procedimentos minimamente invasivos. 
Globalmente, a potencialidade de hidrogéis injectáveis de alginato como sistemas 
formados in situ para a distribuição de células vasculares foi demonstrada.  
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Em síntese, focando-se na necessidade de melhorar a vascularização nas 
estratégias de regeneração óssea, as principais conclusões desta tese decorrem da 
estreita interligação entre células osteoprogenitoras e endoteliais, nomeadamente: i) 
as ECs aumentam a diferenciação e proliferação de MSCs; ii) MSCs imobilizadas em 
alginato modificado com RGD estimulam a formação de estruturas tubulares por parte 
de ECs; iii) o alginato modificado com RGD proporciona um ambiente 3D adequado à 
adesão, sobrevivência, migração e organização de ECs. Finalmente, os resultados 
obtidos revelam que o hidrogel de alginato modificado com RGD representa um bom 
candidato para a imobilização e distribuição de células do osso e endoteliais 
subjacentes a estratégias de regeneração óssea minimamente invasivas. 
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Résumé 
 
Le tissu osseux est l’un des rares organes capable de se reconstruire, même à 
l’âge adulte. En effet, l’os peut se ressouder après une fracture ou peut être renouvelé 
lorsqu’il vieillit. Cependant, dans le cas de pertes osseuses trop importantes (maladie 
congénitale, traumatisme, exérèse de kyste ou tumeur), il est nécessaire d’avoir 
recours à un traitement. De nos jours, les techniques de reconstruction proposées ne 
sont pas adéquates et il apparaît donc essentiel de considérer de nouvelles stratégies.  
Cette thèse porte sur une stratégie d’ingénierie du tissu osseux basée sur le 
développement d’un biomatériau injectable qui serait associé à des cellules souches 
mésenchymateuses (MSCs) et des cellules endothéliales (ECs). A terme, ce système 
pourrait à la fois combler une perte osseuse et stimuler la réparation naturelle de l’os. 
Dans un premier temps, ce travail a étudié l’hypothèse selon laquelle un système 
de coculture synergique entre les MSCs et les ECS peut stimuler la prolifération et la 
différenciation des MSCs. Il a déjà été démontré que les ECs pouvaient induire la 
différenciation ostéogénique in vitro et in vivo, lorsqu'elles étaient en contact direct 
avec les cellules stromales de moelle osseuse. Cependant, contrairement à des 
travaux publiés précédemment portant sur l’interrelation entre les ECs et les MSCs, 
cette étude a été réalisée sur des durées plus longues, à savoir trois semaines au lieu 
de 1 à 6 jours. De plus, des densités cellulaires différentes des deux types de cellules 
ont été considérées. Par ailleurs, plusieurs milieux de culture ont été testés et la 
capacité de différenciation ostéogénique des MSCs dans un milieu non ostéogénique 
mais en présence des ECs, a été soigneusement analysée. Les résultats ont démontré 
qu’en coculture avec les cellules endothéliales de veine ombilicale (HUVECs), la 
différenciation ostéogénique des MSCs est engagée (voire même véritablement 
stimulée, selon les ratios de cellules utilisés), et la prolifération des MSCs augmente de 
manière significative. Par conséquent, les ECs semblent non seulement moduler le 
phénotype des MSCs, mais aussi leur taux de prolifération. 
Dans un contexte clinique et afin de développer un système injectable capable 
de délivrer des MSCs à un site de lésion, ces cellules ont été immobilisées à l'intérieur 
de microsphères d'alginate sur lequel a été greffé de manière covalente la séquence 
peptidique arginine-glycine-aspartique (RGD). Ce réseau polymère hydrophile fourni 
un support 3D pour les MSCs. Les analyses montrent que l’activité métabolique des 
cellules immobilisées augmente au cours du temps. Les cellules semblent capables de 
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se fixer à la matrice 3D en créant de courtes extensions cellulaires. Enfin, lorsque l’on 
induit leur différenciation, les MSCs s’engagent dans la lignée ostéogénique. 
Le tissu osseux étant un tissu très vascularisé, la stimulation de la 
vascularisation est fondamentale lorsque l’on envisage une stratégie de régénération 
osseuse. Les ECs sont connues pour jouer un rôle clé dans ce processus de 
vascularisation car elles constituent la paroi interne des vaisseaux sanguins. Il a été 
aussi démontré que les cellules osseuses sont capables de sécréter un facteur de 
croissance essentiel à l’angiogenèse, le VEGF (vascular endothelial growth factor), et 
pourraient ainsi avoir une influence sur les ECs. Par conséquent, la capacité des 
MSCs à stimuler les ECs après leur co-immobilisation dans les microsphères d’alginate 
fonctionnalisé avec la séquence peptidique RGD a été également étudiée. Les MSCs 
produisent du VEGF qui diffuse à travers le réseau d'hydrogel, passe dans le milieu 
environnant et stimule la capacité des ECs à former des structures tubulaires au sein 
d’une membrane basale reconstituée (Matrigel). 
Une autre façon de promouvoir l'angiogenèse consiste en la prévascularization in 
vitro d'un biomatériau. Des études de thérapies cellulaires offrent une approche 
intéressante pour la revascularisation des tissus. Cependant, et malgré les besoins 
cliniques urgents de stratégies de revascularisation efficaces, l'immobilisation de 
cellules vasculaires viables dans des matrices 3D a été difficile à réaliser. Ici, la faculté 
de l'alginate fonctionnalisé à immobiliser et délivrer des HUVECs in vitro a été évaluée. 
Les HUVECs ont été capables de proliférer et de maintenir leur activité métabolique 
pendant au moins 48h après leur immobilisation au sein de la matrice d'alginate. En 
outre, les cellules ont été en mesure de créer une organisation 3D ainsi que des 
réseaux cellulaires et de migrer vers une couche de Matrigel lorsqu’elle existe. Les 
microsphères étant préparées à partir de solutions aqueuses capables de réticuler in 
situ, cette stratégie paraît adaptée à la formation de réseaux cellulaires, la migration 
des cellules ainsi que la délivrance des ECs au site de la lésion tout en utilisant une 
procédure chirurgicale peu invasive. Les hydrogels injectables tels que l'alginate 
constituent un système de délivrance in situ de cellules vasculaires prometteur.  
En résumé, cette thèse s’est intéressée à la nécessité d'améliorer la vascularisation 
dans les stratégies de régénération osseuse et ses principales conclusions sont 
basées sur la relation étroite entre les cellules ostéoprogénitrices et les cellules 
endothéliales, à savoir: i) les ECs favorisent la différenciation et la prolifération des 
MSCs ; ii) les MSCs immobilisées dans l’alginate fonctionnalisé avec la séquence RGD  
stimulent la formation de structures tubulaires par les ECs ; iii) la matrice d’alginate 
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modifié avec la séquence RGD fournit un environnement 3D adéquat permettant 
l'adhésion, la survie, la migration et l'organisation des ECs. Finalement, une matrice 
d'alginate modifié avec la séquence RGD apparaît être une stratégie d’ingénierie du 
tissu osseux appropriée, permettant l’immobilisation et la délivrance de cellules 
osseuses et endothéliales ainsi qu’une procédure chirurgicale peu invasive.  
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1. BONE  
 
 
1.1. An Overview 
 
Bone is a highly specialized form of connective tissue that constitutes part of the 
endoskeleton of vertebrates and is associated to several important functions: internal 
support, protection, shape, blood production, mineral storage and homeostasis, 
movement, detoxification and sound transduction. It can be classified according to its 
shape: long bones (e.g. thigh, leg, arm), short (e.g. wrist, ankle), flat (e.g. cranium) 
and irregular (e.g. spine bones) 1. Bone is composed of an organic matrix that is 
reinforced by hydroxyapatite, salt deposits of calcium and phosphate. This organic 
matrix consists 95% of collagen type I (95%) and 5% of proteoglycans and several 
noncollagenous proteins 2. 
Morphologically bone is not a uniform solid material but is composed of two 
types of tissues: cortical or compact and sponge or trabecular bone (Fig. 1). Cortical 
bone is rigid and dense, being found mainly in the outer regions of long bones or 
shells of other bones. Trabecular bone, which has a high porosity and is less 
organized, consists of a network of flat or needle-shaped trabeculae. The differences 
in morphology of the two types of tissue are associated to their major functions. In on 
hand, cortical bone provides the mechanical and protective functions and, on the 
other hand, cancellous bone provides the metabolic functions 2. 
 
 
 
Figure 1. Schematic representation of the two morphological tissues (cortical and 
trabecular bone) that coexist in a long bone 3. 
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Cortical bone consists of repeating units, Harversian systems or osteons. Each 
osteon has concentric layers of mineralized matrix called lamellae, which are 
deposited around a central canal, the haversian canal, containing blood vessels and 
nerves 1. Blood vessels connect to near osteons through anastomosing vessels in 
Volkmann’s canals.  
 
Bone is a living tissue comprising, apart from blood and nerves, four types of 
cells that contribute to its homeostasis: osteoblasts (bone forming cells), osteocytes 
(mature bone cells), osteoclasts (resorb or break down bone) and bone lining cells 
(cover inactive bone surface). Cellular communication between the bone cells, namely 
osteoblasts, osteocytes and (pre-)osteoclasts is essential for bone remodeling and 
therefore bone integrity 4. Is the coordinate action of resorptive and formative cell 
populations that lead to new bone formation and, consequently, skeleton integrity 5. 
Noteworthy, in the last decade several reports have come out demonstrating that 
bone homeostasis is also under the influence of central and peripheral neural control, 
establishing a link between the nervous system and bone 6. 
Osteoblasts are fully differentiated cells responsible for bone development, 
growth, function, repair and maintenance 7. They secrete type I collagen and 
noncollagenous proteins (bone sialoprotein, osteocalcin, osteonectin and 
osteopontin). Typically, an osteoblast is a protein producing cell with a prominent 
Golgi apparatus and a well developed rough endoplasmic reticulum 2. 
Osteocytes are mature osteoblasts entrapped in the bone matrix and are 
responsible for its maintenance, constitute 90% to 95% of all bone cells in adult bone 
and are the longest lived bone cells. These cells have been found to have several 
functions, such as acting as an orchestrator of bone remodeling through regulation of 
both osteoclast and osteoblast activity and also by soluble factors production 8, 9. 
Bone lining cells are flat, elongated, inactive cells (with few cytoplasmic 
organelles) that cover bone surfaces that are not undergoing bone formation or 
resorption 2. 
Osteoclasts are large multinucleated bone-resorbing cells that are unique in their 
ability to degrade both the inorganic calcium matrix and the organic collagen matrix 2. 
Bone resorption is a process highly dependent on a series of external stimuli, such as, 
matrix type, remodeling status, hormones involved in calcium homeostasis, genotype 
and inflammation 10.  
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Two different mechanisms are responsible for the development of bones: 
intramembranous (e.g. calvarial bones and mandibles) and endochondral ossification 
(e.g. long bones of the axial and appendicular skeleton) 11. Both processes involve 
coordinated growth, differentiation, function and interaction of different cell types.  
Intramembranous ossification involves the formation of bone directly, without 
intermediate formation of cartilage. Mesenchymal cells aggregate and differentiate into 
osteoblasts that deposit bone matrix rich in type I collagen, which becomes mineralized 
12, 13. 
The endochondral ossification process involves the recruitment, proliferation and 
differentiation of mesenchymal cells into chondrocytes, forming a cartilage template of 
the future long bone 13. Chondrocytes in the center become hypertrophic, while cells in 
the perichondrium differentiate into osteoblasts forming a bone collar 12. Then, the 
hypertrophic cartilage core is invaded by blood vessels, eroded and replaced by bone 
and marrow (the primary ossification center). This process continues at the growth 
plate, mediating longitudinal bone growth. Later, vessels invade the avascular 
epiphyseal cartilage and initiate a secondary center of ossification. Ultimately, the 
growth plates close and longitudinal growth stops.  
 
 
1.2. An Amazing Organ - Regeneration of a Bone Fracture 
 
Bone fracture healing is a remarkable process, which ends with bone anatomy 
and complete regeneration within 6-8 weeks 14. Although bone formation is a complex 
process, the three-dimensional arrangement of cells and matrices is straightforward. 
Moreover, fracture healing is a process that recapitulates certain aspects of skeletal 
growth and depends on the cooperation of several elements, namely: i) specific cell 
types (Fig. 2); ii) extracellular matrix; iii) soluble molecules and iv) mechanical 
environment 15, 16. 
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Figure 2. Cellular participants in the fracture repair processes 16. 
 
 
Fracture healing can be divided into direct (primary) and indirect (secondary) 
fracture healing 13. Direct healing occurs only when there is anatomic reduction of the 
fracture fragments due to rigid internal fixation and decreased intrafragmentary strain 
and there is no callus formation. Indirect healing involves the combination of 
intramembranous and endochondral ossification and there is callus formation. 
Noteworthy, the indirect healing is associated with the majority of bone repair 
processes, where intramembranous ossification occurs few days after fracture and 
endochondral ossification that occurs close to the fracture site over a period of up to 28 
days 17 . 
After bone fracture there is a disruption of the marrow architecture and of blood 
vessels within and around the fracture site. The repair of a fracture by callus formation 
is a well-organized process that can be divided in four different stages, which are 
hematoma formation, soft callus formation (chondrogenesis), hard callus formation 
(osteogenesis) and bone remodeling (Fig. 3) 18. 
 
 
 
Figure 3. Stages of fracture repair: (a) hematoma formation and inflammation; (b) soft callus 
formation; (c) hard callus formation; (d) bone remodeling 18. 
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After injury of the musculoskeletal system, disruption of blood vessels leads to 
activation of the coagulation cascade and formation of hematoma, which encloses the 
fracture area, serves as a source of signaling molecules (interleukins, tumor necrosis 
factor-a, fibroblast growth factor, insulin-like growth factor, platelet-derived growth 
factor, vascular endothelial growth factor and transforming growth factor) and provides 
pathways for cellular migration (Fig. 3a) 19. The first few days post-fracture are 
characterized by an inflammatory phase. Inflammatory cells, fibroblasts, and stem cells 
are recruited to the site, and new blood vessels are formed from the pre-existing ones 
(angiogenesis) (Fig. 3b). Meanwhile, undifferentiated mesenchymal cells along with the 
periosteum form a large cartilaginous mass both outside the cortices, an external 
callus, and within the cortices, an internal callus (Fig. 3b) 20. The main role of this 
region is to mechanically stabilize the fracture site and is composed of fibrous tissue 
and new cartilage 14. Subsequently, the internal callus becomes mineralized with 
calcium hydroxyapatite. Capillaries from adjacent bone invade the calcified cartilage, 
increasing the oxygen tension. The hard callus is formed of woven bone and cartilage 
and connects the two fracture ends (Fig. 3c). In the final phase, bone remodeling, the 
large fracture callus is replaced by secondary lamellar bone (Fig. 3d). The size of the 
callus is reduced to that of the pre-existing bone at the damage site, the vascular 
supply reverts to a normalized state and the bone cortex acquires the pre-existing 
architecture 18. 
 
 
1.3. A Complex Organ - Different Elements in Bone Regeneration 
 
Bone regeneration is a complex physiological process that involves the 
coordinated participation of several cell types (e.g. haematopoietic, immune, 
mesenchymal stem, nerve and endothelial cells), growth factors/cytokines (e.g. 
fibroblast growth factor, transforming growth factor, bone morphogenetic protein, 
insulin-like growth factor, platelet-derived growth factor, vascular endothelial growth 
factor) and extracellular proteins. These factors regulate the cascade of molecular 
events by influencing different steps in the osteoblast and chondroblast pathway such 
as migration, proliferation, chemotaxis, differentiation, inhibition, and extracellular 
protein synthesis 13. Table 1 lists key molecules and cells involved in bone repair. 
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Table 1 – Key molecules and cells involved in bone repair 15. 
Key factors Functions In vivo and in vitro effects 
Extracellular messengers 
 
 
IL-1, IL-6, TNFa Elicit inflammation and 
migration 
In vitro they inhibit osteoblastic differentiation, but in vivo 
TNFa is crucial for bone repair; the role of IL-6 is 
controversial (anti-or pro-osteogenic probably, depending 
on soluble IL-6 receptor) 
 
SDF1 Chemotactic factor Allows MSCs homing both in vitro and in vivo 
 
TGFß Mitogenic factor, 
osteogenic factor 
Can induce osteoblast differentiation at the early stage of 
immature cells but can also inhibit osteogenesis in 
committed cells 
 
BMP2 Osteogenic factor Osteochondrogenic factor; might initiate bone formation 
and bone healing and can induce expression of other 
BMPs 
 
BMP4 Osteogenic factor Osteochondrogenic factor in vivo and in vitro 
 
BMP7 Osteogenic factor Osteogenic factoring in vivo and in vitro; active on more 
mature osteoblasts 
 
Noggin BMP2, 4 and 7 specific 
inhibitor 
 
Suppresses osteoblastic differentiation 
FGFb Angiogenic and mitogenic 
factor, osteogenic factor 
(controversial) 
 
Mutations induce chondrodysplasia and craniosynostosis; 
can stimulate Sox9; might be a negative regulator of 
postnatal bone growth and remodeling 
 
IGF-I, II Mitogenic factors, 
osteogenic factors 
Stimulate growth plate formation, endochondrate 
ossification and bone formation by osteoblasts 
 
VEGF Angiogenic and 
vasculogenic factor 
Most potent angiogenic and vasculogenic factor; crucial at 
the onset of bone formation 
 
PlGF Angiogenic and 
vasculogenic factor 
Induces proliferation and osteogenic differentiation of 
MSCs; crucial for vascularization 
 
PDGF Mitogenic and chemotactic 
factor 
Highly mitogenic factor and chemotactic for MSCs, 
osteoblasts and perivascular cells 
 
Wnts Mitogenic and osteogenic 
factors 
Depending on Wnt type, crucial for osteoprogenitor 
proliferation; can also inhibit final osteoblast maturation 
 
DKK1 Inhibitor of Wnt signaling Strongly inhibits osteogenesis of MSC and osteoprogenitor 
cells; can stimulate terminal maturation 
 
Ihh Osteochondrogenic factor Pivotal role for growth plate and endochondral formation; 
can inhibit osteoblast differentiation; might induce PTHrP 
expression 
 
PTHrP Osteochondrogenic factor Pivotal role for growth plate and endochondral formation; 
can induce or inhibit osteogenesis 
 
OPG Decoy receptor of RANKL, 
inhibition of RANKL 
Strongly inhibits bone resorption and has a pivotal role in 
bone remodeling 
RANKL Induces 
osteoclastogenesis 
Strongly stimulates bone resorption and has a pivotal role 
in bone remodeling 
 
M-CSF Induces 
osteoclastogenesis 
Crucial for osteoclastogenesis 
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Gastrointestinal 
serotonin 
 
Neurotransmitter inhibiting 
osteogenesis 
 
Expressed by enterochromatin cells, inhibits bone 
formation and is repressed by Lrp5 
 
Intracellular messengers 
 
 
MAPKs Transduce osteogenic 
signaling by 
phosphorylation 
 
Crucial for regulation of intracellular signaling induced by 
osteogenic factors (still controversial) 
 
PKA/CREB Transduce osteogenic 
signaling 
Can transduce osteogenic signaling (still controversial); 
possible indirect effect 
 
ß-Catenin Osteogenic transducer 
factor 
Pivotal role in transducing osteogenic signal from Wnt and 
is negatively regulated by GSK3b 
 
Runx2 Early osteogenic 
transcription factor 
 
Master regulator of early osteogenesis; runx2-/-mice die, 
with no bone formation 
Osterix Late osteogenic 
transcription factor 
Master regulator of late osteogenesis, inhibiting 
chondrogenesis  
 
Dlx5 Osteogenic homeobox 
protein 
Induces osteoblast maturation but inhibits osteocyte 
formation 
 
Msx2 Osteogenic homeobox 
protein 
Induces proliferation of immature cells; responses depend 
on Dlx5 quantity 
 
NF-kB Inflammation transducer 
factor, inhibits 
osteogenesis 
 
Inhibits the differentiation of MSCs and committed 
osteoblastic cells 
 
Cells 
 
 
MSCs Origin of osteoblasts Can form bone in vivo and osteoblasts in vitro 
 
Osteoblasts Osteogenic professional 
cells 
 
Generate bone formation 
Endothelial cells Blood vessels formation Stimulate osteogenic differentiation and blood vessel 
formation 
 
Nerve cells  
 
Neurotransmitter 
production (NPY) 
Bone homeostasis; in vitro enhance osteoprogenitor cells 
differentiation 
Abbreviations: IL – interleukin; TNF – tumour necrosis factor; SDF – stromal derived factor; TGF 
– transforming growth factor; BMP – bone morphogenetic protein; FGF – fibroblast growth 
factor; IGF – insulin-like growth factor; VEGF – vascular endothelial growth factor; PlGF – 
placental growth factor; PDGF – platelet-derived growth factor; Ihh – indian hedgehog; PTHrP – 
parathyroid hormone-related protein; OPG – osteoprotegerin; RANKL – receptor activator of 
nuclear factor kappa-B ligand; M-CSF – macrophage colony-stimulating factor; MAPKs – 
mitogen-activated protein kinase; NF-kB – nuclear factor-kB; MSCs – mesenchymal stem cells; 
NPY – neuropeptide Y. 
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1.4. A Problem to be solved 
 
Bone is one of the few organs that retains the potential for regeneration in adult 
life, as it possess the ability to heal and to remodel 21. This ability is mainly due to the 
coordinated interaction of several elements. For instance, many local and systemic 
regulatory factors, cytokines and hormones, as well as extracellular matrix interact with 
several cell types. However, in several clinical settings bone is not able to heal by itself, 
such as fusion of bones, reconstruction of shattered bones, stimulation of bone growth 
to help anchor an artificial joint or other implant and filling of bone defects caused by 
trauma, tumours, infections, biochemical disorders and abnormal skeletal development 
22, 23. The current standard treatment for some of these problems is based on the use of 
bone-grafting materials that are divided into two groups: natural and synthetic bone 
grafts 24. Natural bone grafts include auto-, allo- (human donors) and xenografts (other 
species). Autologous bone graft is considered the “gold standard” for bone repair and 
regeneration by many surgeons, mainly due to lack of immunogenic reaction and 
optimal biological performance in terms of osteogenicity, osteoinductivity and 
osteoconductivity 23. However they present several limitations, namely the reduced 
availability and the risks associated to the harvesting, an additional surgical procedure, 
donor site morbidity, post-operative pain and infection 25. On the other hand, allografts 
and xenogratfs are widely available and there is no need for an additional surgery. 
However, in both situations there is the risk of immunoreaction and since they pass 
through several processing techniques, their osteoinductive and osteoconductive 
potential are reduced 23, 25, 26. To overcome the above limitations of natural gratfting, a 
large number of synthetic grafts have been designed over the past decades. They can 
be divided in different groups according to the base material: metals (e.g. titanium and 
its alloys, steel, cobalt-chromium), ceramics (e.g. calcium phosphate, alumina, glass 
ceramics), polymers (e.g. polylactic acid, polyglycolic acid, poly(methyl metacrilate), 
polyurethane, polyethylene) and composites of these three groups (e.g. hydroxypatite 
reinforced with high density polyethylene, metallic implants coated with calcium 
phosphate) 23, 24. These synthetic materials present several advantages, such as large 
availability, lack of antigenic response and can be easily tailored to a specific 
application. Still, the biological performance of these synthetic grafts regarding initiation 
and support of bone growth are inferior to those of natural grafts 23. One way to 
overcome this consists on adding cells and/or growth factors to those materials, giving 
Chapter I 
 
 
 11 
rise to more biological candidates capable to restore, maintain or improve bone 
function 17. 
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2. BONE TISSUE ENGINEERING 
 
 
2.1. Helping Bone to Regenerate 
 
Since the early 1990s several approaches have been developed that are of 
particular interest to restore, maintain and improve bone function that include the 
combination of engineering and life sciences to incorporate the biological performance 
that is generally missing in synthetic bone substitutes 27. Tissue engineering constitutes 
a promising approach by using three-dimensional structured biomaterials as 
extracellular matrix in combination with stem cells as cell source and/or biologically 
active molecules (Fig. 4) 26. Biomaterials scaffolds are investigated to not only to serve 
as cell carriers to providing mechanical support, but also to actively influence cell 
behavior, such as cell adhesion, proliferation, differentiation and function 28.  
 
 
 
Figure 4. The typical engineering approach. 1) Cell removal; 2) Cell expansion in culture; 3) 
Cell seeding onto an appropriate scaffold incorporating suitable growth factors and cytokines; 4) 
Cell culture; 5) Re-implantation of engineered tissue in the damaged site.  
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2.2. Mesenchymal Stem Cells – An Outstanding Cell Population 
 
The ideal cell source for bone tissue engineering should be easily expandable to 
higher passages, non-immunogenic and have a protein expression pattern similar to 
bony tissue. Cell sourcing and its characterization is one of the concepts with higher 
priority in the field of tissue engineering. More precisely, and according to Johnson and 
colleagues, stem cells science is the second most strategic concept and remains a 
critically important focus for the tissue engineering field 29. 
A vibrant cell population is a mandatory first element for an unimpeded bone 
repair process, such as, multipotent mesenchymal cells or mesenchymal stromal cells 
(MSCs). MSCs have been utilized to enhance fracture healing in a number of in vitro 
and in vivo studies 19. The cell-based concept to repair bone defects was first 
established using fresh autologous bone marrow combined with porous calcium 
phosphate ceramics 30.  
MSCs were first reported in the 60’s by Friedenstein et al. as fibroblast-like cells 
that could be isolated from the bone marrow through their capacity to adhere to plastic 
in culture and to differentiate into adipocytes, chondrocytes and osteocytes 31. 
Nowadays, MSCs have been isolated from several tissues, including adipose tissue, 
liver, muscle, amniotic fluid, synovium, placenta and umbilical cord 32. However, the 
principal source of MSCs for most preclinical and clinical studies is the bone marrow.  
The true identity of MSCs has often been confused by different laboratories, 
which employ different isolation and in vitro culture methods, combined with different 
sources. To address this inconsistency between nomenclature and biological 
properties and to clarify terminology, the International Society for Cellular Therapy 
(ISCT) provided the following minimum criteria for defining multipotent mesenchymal 
stromal cells 33: 
a) Plastic-adherent under standard culture conditions; 
b) Positive for expression of CD105, CD73 and CD90, and absent for 
expression of hematopoietic cell surface markers, namely CD34, CD45, 
CD11a, CD19 and HLA-DR; 
c) Under specific stimulus, cells should differentiate into osteocytes, adipocytes 
and chondrocytes in vitro. 
 
Despite of some questions that remain unanswered there is substantial evidence 
supporting the use of MSCs as a biological therapeutic for a diverse range of clinical 
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applications:  
 
a) Easily accessible isolation: MSCs can be obtained from clinically available 
sources, such as, bone marrow, adipose tissue and cord blood, which are 
considered candidates for MSCs production for clinical applications 34, 35. 
Bone marrow aspirate is considered to be the most accessible and enriched 
source of MSCs and is the principal source of MSCs for most pre-clinical and 
clinical studies 36, 37. However, the harvest of bone marrow is a highly 
invasive procedure and the life span and differentiation potential of MSCs 
from this source decline with increasing age 34.  
Adipose tissue has great potential as stem cell source for tissue engineering 
applications, mainly due its high availability. Adipose stem cells (ASCs) can 
be obtained as a “waste” from surgical procedures and/or harvested from 
humans through liposuctions. The major disadvantage of this source is 
contamination by other cells types, which can negatively influence the 
proliferation and/or differentiation of ASCs. To overcome this, new isolation 
methods have emerged, for instance based on the use of immunogenic 
beads 38.  
The umbilical cord blood is a source of MSCs with low immunogenicity and 
with some immunosuppressive functions 39. This source has the advantage 
of being widely available (normally it is discarded) and presents no risk for 
the mother or the newborns. 
 
b) High expansion potential in culture: For large-scale production of MSCs, 
successive passages are needed to obtain a highly enriched population of 
MSCs. Additionally, the ideal culture conditions should be capable to 
maintain MSCs with (a) phenotypic and functional characteristics similar to 
those exhibited in the original niche, (b) indefinite proliferation and (c) the 
capacity to differentiate into multiple lineages 40. In the past decade several 
studies emerged concerning optimal culture conditions for clinical scale 
production of MSCs 41-45. 
Comparing the previous MSCs sources mentioned, bone marrow, adipose 
tissue and cord blood, they present different success rate in terms of MSCs 
isolation and proliferation capacities. For example, MSCs from cord blood 
present the lowest isolation efficiency, but the highest expansion potential 34. 
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c) Presumptive plasticity: Some studies showed that MSCs in the adult 
organism could differentiate in vitro into unexpected directions, beyond the 
well-know ability of these cells to give rise to mesodermal cell lineages 
(osteoblast, chondroblast and adipocyte) and cross the germinal boundaries 
(cardiomyocytes, hepatocytes, endothelial cells and neuronal cells) 46-50. 
However, due to lack of experiment reproducibility (isolation, media and 
culture period) the plasticity of MSCs is still a debatable topic 47, 51, 52. 
 
d) Immunosuppressive properties and allogeneic transplantation: Great interest 
is now being raised in the capacity of MSCs to modulate the immune 
response. In fact, MSCs do not induce considerable alloreactivity due to 
several unique characteristics, namely: inhibition of T-cell proliferation; 
modulation of B-cell proliferation, migration and immunoglobulin production; 
inhibition of natural killer cells proliferation; possible interference with dentritic 
cell functions (inhibition of cell maturation); and influence the function of 
neutrophils and macrophages 35, 37, 52, 53. The poorly immunogenicity and the 
available data supports the concept that the transplantation of these cells 
into an allogeneic host may not require immunosuppression 54-56. In fact, 
allogeneic MSCs could be used as therapeutic agents to combat graft versus 
host disease and Crohn’s disease, both involving the strong 
immunoregulatory capacity of these cells. A company (Osiris Therapeutics 
Inc., USA) is currently evaluating the use of adult MSCs as therapeutic 
agents in both diseases, in phase III clinical trials 37, 53. 
 
e) Paracrine-mediated effects: MSCs have the capacity to secrete a broad 
spectrum of bioactive macromolecules (growth factors and chemokines) 
capable of creating a regenerative microenvironment that may enhance the 
normal wound healing, stimulate proliferation and differentiation of tissue–
intrinsic progenitor cells, decrease inflammatory and immune reactions 52, 53, 
57. 
 
f) Homing and migratory behavior to sites of tissue injury: MSCs have exhibited 
capacity to leave the bone marrow, circulate in the blood and home to injured 
tissues 58, 59. Therefore, the use of MSCs has been particularly hailed due to 
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its presumed capacity to selectively migrate to sites of inflammation/injury 
when injected intravenously 37, 52. However, the molecular mechanisms 
underlying MSCs migration are not yet fully understood.  
 
g) Ethical considerations: Although embryonic stem cells (ESCs) have greater 
potential than adult stem cells, their use is still limited by lack of 
understanding about how to specifically regulate ESCs differentiation, their 
association with tumorigenicity and several ethical issues that are raised: 
destruction of embryos, creation of embryos for research (payment to oocyte 
donors and medical risks of oocyte retrieval) 37, 39, 60. Therefore, adult stem 
cells represent a less controversial cell source (isolated from adult tissues) 
and their use in clinical practice has also been better documented and 
investigated.  
 
 
2.3. Key Partakers in Bone Regeneration 
 
The bone regeneration process involves the coordinated participation of 
haematopoietic and immune cells in conjugation with vascular and bone cell precursors 
61. During this process mesenchymal stem cells and endothelial cells are key partakers 
62. The important relationship between blood vessels and bone formation was first 
mentioned in 1763 by Albrecht von Haller who wrote: “the origin of bone is the artery 
carrying the blood and in it the mineral elements” 63. However, in the following years, 
more attention was dedicated to the role of osteoblasts in bone formation. It was just in 
the 20th century that this relationship was revived, after the suggestion that tissues 
produce substances that initiate osteogenesis, such as a vascular stimulating factor 
(VSF), that appears in bone damage sites 64. Nowadays, it is known that an adequate 
or proper bone vascularization is needed for bone formation and bone mass increase 
18, 65, 66. The inhibition of angiogenesis during fracture repair leads to the formation of a 
fibrous tissue. Moreover, the lack of blood supply is one of the risk factors during bone 
healing. Other risks include poor apposition of fractured bone ends, interposition of soft 
tissues or necrotic bone between bone fragments, inadequate immobilization, infection, 
drug use, advanced age and systemic disorders 67, 68. 
As previously mentioned, bone is a highly vascularized tissue where blood 
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vessels are in intimate association with bone tissue. This tight correlation has been 
recently explored in several works 69-90. Endothelial cells (ECs), the cells lining blood 
vessels, have been shown to produce a number of local and systemic mediators that 
influence the proliferation, differentiation and function of osteoprogenitor cells. On the 
other hand, osteoprogenitor cells secrete factors that enhance differentiation and 
survival of endothelial cells. Accordingly, Wang demonstrated that 1,25-
Dihydroxyvitamin D3 enhances the production of vascular endothelial growth factor 
(VEGF) by osteoblasts, thereby stimulating VEGF receptors of ECs which, in turn, 
produce osteotropic growth factors (insulin-like growth factor I (IGF-1) and 
endothelium-1 (ET-1)) 87. Lamparter showed that angiotensin II, generated by ECs, 
stimulates proliferation and collagen synthesis of non mature osteoblasts 91. Villars and 
colleagues also demonstrated that bone marrow stromal cells (BMSCs) express and 
synthesize VEGF, that human umbilical vein endothelial cell (HUVEC) conditioned 
medium has a proliferative effect on BMSCs and that early osteoblastic marker levels 
increase when these are co-cultured with HUVECs in direct contact 81. Later, this group 
suggested that the gap junction connexin 43, which is expressed in both cells, has a 
significant contribution in osteoblastic differentiation 92. Deckers et al. studied the 
expression of osteoblast-derived VEGFs and their receptors and proposed that they 
modulate endothelial and osteoclast functions as well as osteoblast differentiation 93. 
Moreover, Kaigler et al. demonstrated that BMSCs secrete sufficient quantities of 
VEGF to enhance survival and differentiation of endothelial cells in vitro and afterwards 
established that ECs significantly increased BMSC osteogenic differentiation in vitro, 
only in direct contact, and that ECs also expressed bone morphogenetic protein 2 
(BMP-2) 77, 94. Noteworthy, in vivo studies where both cells were co-transplanted on a 
biodegradable polymer resulted in greater bone formation than when osteoprogenitor 
cells were implanted alone: Kaigler el al. used a poly(lactic-co-glycolic acid) scaffold 
and Grellier et al. immobilized the cells within a RGD-modified alginate 71, 77. Overall, 
two main dialogues were identified: a paracrine effect through VEGF, BMP-2, IGF, ET-
1 production and a juxtacrine mechanism by gap junctional activity between the two 
cell types 89, 95. The available data so far strongly supports a relevant role of vascular 
cells in bone tissue regeneration. 
Furthermore, an appropriate vascular network is necessary to support the 
metabolic needs of a forming tissue mass. Vascularization of engineered tissue 
constructs may improve the success rate after transplantation, since the survival of 
implanted cell relies on nutrients and waste diffusion between them and the 
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vasculature in the surrounding host tissue 96-99. Therefore, attempts to mimic 
vascularization in engineered bone tissues that would lead to more clinically relevant 
cell-based therapies are being developed. These strategies are based on growth factor 
release, scaffold design and engineering, decellularized matrices and culture of 
endothelial cells in the 3D scaffold 100. The design of matrices able to deliver growth 
factors in a controlled way instead of a bolus delivery or systemic administration 
present several advantages; for instance, they allow a longer exposure period to low 
and localized doses of the growth factor 101. Different biomaterials have been shown to 
provide varied rates of success for localized and sustained release delivery of growth 
factors, such as for instance injectable alginate hydrogel, poly(lactide-co-glucolide) 
microspheres, collagen scaffolds, and fibrin matrix 102-105. 
Scaffolds may be also designed to direct vascularization through 
microchanneling, molecular gradients or micro-patterning that would allow to control 
oxygen and nutrient gradients, cell alignment and concentration gradients of growth 
factors 98, 100, 106. There are several micropatterning techniques that were developed to 
regulate angiogenesis on biomaterials: photolithography, microcontact printing, 
micromolding and three dimensional laser photolithography 107. 
In the past few years a growing interest in in vitro prevascularization of different 
biomaterials for bone regeneration has emerged into the limelight 75, 76, 82, 84, 85. This 
approach is based on the concept that a network of microvessels may be engineered 
in vitro by combining scaffolds with endothelial cells, providing a starting point for 
vascularization. Aiming bone regeneration several studies have been conducted based 
on cocultures of bone and endothelial cells. Unger and co-workers evaluated the 
vascularization potential on four different biomaterials previously studied for bone 
tissue engineering: porous calcium phosphate (hydroxyapatite), porous nickel-titanium 
and silk fibroin mesh 85. Cocultures of microvascular endothelial cells (MECs) and 
primary osteoblasts self-assembled on these biomaterials, and MECs formed 
microcapillary-like structures without adding any exogenous angiogenic factor. 
Hofmann and colleagues were able to improve vascularization (formation of vessel-like 
structures) by seeding HUVECs with primary osteoblasts on a polyurethane scaffold 76. 
Also using primary osteoblasts but with outgrowth endothelial cells (endothelial 
progenitor cells) Fuchs et al. were able to enhance pre-vascularization on a silk fibroin 
mesh and on a starch polycaprolactone scaffold 82, 84. 
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Although vascularization remains an unsolved challenge in tissue engineering, 
encouraging developments have been reported on the in vitro growth and maintenance 
of self-assembled biological vascular networks 108, 109.  
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3. INJECTABLE CELL-SYSTEMS FOR BONE REGENERATION 
 
 
3.1. Cell Delivery 
 
As the field of tissue engineering progressed, improvements in the fabrication of 
more refined and tailored cell based therapies are emerging to replace, repair or 
enhance the function of damaged tissues or organs. The ability to combine cells with 
biomaterials to create “living cell medicines” has open new doors.  
The success of cell delivery systems is dependent on the use of a biomaterial 
vehicle/scaffold that should allow controlling three-dimensional shape, guide tissue 
development and permit the convenient delivery of cells into the patient 110, 111. 
Therefore, such biomaterials should allow adhesion, spatial distribution, protection and 
guidance of cells 110. Due to its great potential, therapeutic cell transplantation has 
become more and more important in regenerative medicine in this last decade 112.  
There are several strategies for cell delivery in skeletal tissue engineering, 
depending on the clinical application: injectable delivery, delivery with soft scaffolds, 
load-bearing cell-seeded replacement biomaterials, delivery of moulded transplants, 
encapsulation for immunoprotection, and use of shape memory constructs for 
minimally invasive surgery 110. For clinical applications, cell delivery through a minimally 
invasive approach may be a desired method, since these systems offer specific 
advantages over preformed scaffolds, such as ease of application, confined delivery 
and improved patient compliance and comfort 113. 
 
 
3.2. Injectable Bone Substitute Materials 
 
With the development of minimally invasive surgical methods, directly injectable 
biomaterials have been investigated in the search for the least possible invasive 
method 114. Therefore, injectable bone substitutes must encompass a range of 
desirable properties to make it an ideal candidate: ability to mold to the shape of the 
bone defect; polymerize when injected into the site; ease of preparation and handling; 
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injectibility; no toxicity; low cost; adequate mechanical properties; appropriate 
cohesion; excellent osteoconductivity, osteoinductivity, biocompatibility and bioactivity 
114, 115. 
The burgeoning number of cutting edge discoveries is leading the design of 
minimally invasive, biomimetic and biodegradable cell-laden vehicles, such as 
microcarriers, microspheres for cell immobilization and in situ gelling biomaterials that 
can be injected into the target injured tissue, promoting cell integration and, 
consequently, tissue repair and regeneration (Fig. 5) 111, 116.  
 
 
 
Figure 5. Injectable bone substitute biomaterials for cell delivery. A) microcarriers; B) 
microspheres for cell immobilization; C) In situ gelling biomaterials. 
 
 
3.2.1. Microcarriers for cell delivery 
 
Microcarriers serve as a cell-seeded system that can be delivered directly into 
the site of injury through injection or arthroscopically or used as templates to propagate 
large numbers of cells that can be recovered for subsequent analysis or transplantation 
117. Microcarriers offer the advantage of providing a large area for monolayer cell 
growth during propagation in a homogenous suspension culture system comparing 
with culture flasks. Therefore, these systems are space saving and cost effective with 
respect to the use of culture media and expensive additives such as growth factors and 
serum. Microcarriers can be combined with other technologies to attain a higher 
performance. For example, Kedong and co-workers combined a glass coated styrene 
copolymer microcarrier with a rotating wall vessel bioreactor to attain higher cell 
proliferation in a coculture system 118. 
The use of microcarriers culture in tissue engineering has only been scarcely 
explored, although there are commercially available microcarriers that can potentially 
be used for that purpose (Table 2) 117, 119, 120. 
Chapter I 
 
 
 22 
Table 2 – Selection of commercially available microcarriers 117, 119, 120. 
Name Material Surface coating Surface charge Diameter (µm) 
Cytodex 1 Dextran None + 131-220 
Cytodex 2 Dextran Collagen + 135-200 
Cytodex 3 Dextran Collagen + 133-215 
Biosilin Polystyrene n/a - 160-300 
P 102-L Polystyrene Polystyrene None 125-212 
RapidCell n/a Glass - 150-210 
ProNectin®F Polystyrene Fibronectin None 125-212 
FACT III Polystyrene Gelatin + 125-212 
Plastic plus Polystyrene None + 125-212 
Collagen Polystyrene Gelatin None 125-212 
Plastic Polystyrene None None 125-212 
Glass Polystyrene High silica - 125-212 
Hillex®II Polystyrene Trimethyl ammonium + 160-180 
Cultispher G Gelatin None  130-280 
Cultispher S Gelatin None  130-280 
Abbreviation: n/a, not available 
 
 
Microcarriers composed of crosslinked dextran matrix (under the tradename of 
Cytodex) are the most commonly used for a wide range of cells. There are three 
different types of dextran-based microcarriers: type 1 - matrix with N, N-
dimethylaminoethyl groups; type 2 - matrix with a surface layer of N,N,N-trimethyl-2-
hydroxyaminopropyl groups; and type 3 - matrix with a thin layer of collagen type I. 
Frauenschuh and co-workers studied the three types of dextran-based microcarriers for 
MSC expansion and conclude that type 1 was the most suitable for MSC attachment 
and proliferation during a cultivation period of 28 days 121. These results were later 
corroborated in a study where the seeding efficiency of MSCs was evaluated on nine 
different commercially available microcarriers: dextran-based types 1 and 3 and seven 
polystyrene-based microcarriers, including five with different surface coatings 
(fibronectin, gelatin, high silica trimethyl ammonium) and two without coating (under the 
tradename ProNectin F, FACT III, Plastic plus, Collagen, Plastic, Glass, Hillex II) 122. 
Schop et al. investigated the best culture conditions for MSCs growing in type 1 
dextran-based carrier and concluded that by adding 30% fresh medium with new 
microcarriers every three days, MSCs showed the longest continuous proliferation 119. 
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Although seeding efficiency studies are essential, good harvest processes that lead to 
high number of viable MSCs capable of retaining their differentiation potential are 
mandatory. For that reason macroporous microcarriers are not suitable since it 
becomes difficult to enzymatically separate cells within the pores. Alternatively, 
nonporous microcarriers should be considered for MSC expansion and further 
detachment. Weber and co-works investigated MSC behavior in five nonporous 
microcarriers: type 1 and 3 dextran-based microcarriers, two based on polystyrene 
(under the tradename of Biosilon and P 102-L) and another one with a glass surface 
(Rapidcell) 120. Although they did not find considerable differences on MSCs growth 
rate among the five carriers, the harvest efficiency was quite different. Dextran-based 
microcarriers presented the lowest efficiency using the five enzymes tested for cell 
detachment. To avoid the use of proteolytic enzyme treatment and to enhance the 
harvest yield, Yang and colleagues conjugated the commercial type 3 dextran-based 
microcarrier with a thermosensitive polymer, poly-N-isopropylamide 123. By simply 
reducing the temperature below 32ºC, MSCs detached and presented lower apoptosis 
and death rates than the ones treated with trypsin. 
Due to harvest difficulties, alternatives to dextran-based microcarriers need to be 
considered for MSCs adhesion and proliferation, such as the use of gelatin-based 
microcarriers (e.g. Cultipher-G and Cultipher-S) 124-126. These microspheres can be 
dissolved with trypsin-ethylenediamine tetraacetic acid (EDTA) or collagenase, and 
almost all MSCs can be recovered without loosing their differentiation potential 127. 
Moreover, to attain readily available constructs, Lippens and colleagues proposed an 
interesting approach by examining the cryopreservation process of gelatin-based cell-
microcarrier constructs 126. They were able to achieve promising results in the pursuit 
for readily available tissue constructs for fast intervention in bone defects.  
Beyond the materials used in commercially available microcarriers, other 
biomaterials have been proposed as cell-seeded systems. These biomaterials present 
several appropriate features that would allow to control cell quality and quantity and, 
therefore, to ensure intact cell phenotype during delivery, namely: chemical 
composition, surface topography, degree of porosity, charge density and sterilization 
117. Several different types of biomaterials have been investigated for microcarrier 
technology, such as: ceramics (e.g. calcium titanium phosphate), bioceramic 
microparticles in a polymeric matrix (e.g. hydroxyapatite particles in a poly(lactide-co-
glycolide) matrix), and polymers (polycaprolactone with interconnected pore channels; 
D,L-lactide-co-glycolide acid microspheres with a biomimetic surface of fibronectin) 128-
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132. 
In general, microcarriers are spherical units with various substrate matrices that 
can be kept in stirred bioreactors. In these systems, cells grow mainly on the spherical 
surface as monolayers or in the pores in the case of macroporous structures 112. As a 
result, a large amount of microcarriers with cells has to be introduced in the body in 
order to obtain a sufficient cell number. To overcome this drawback, Su and co-authors 
developed a novel open and hollow shell-structure cell microcarrier based on gelatin for 
cell transplantation, which allowed cells to attach and proliferate on both outer and 
inner surface of the microcarrier 112. This strategy aims to decrease the number of 
microcarriers necessary to achieve an adequate amount of cells and, subsequently, the 
volume in the injection system. In another alternative approach, bioactive calcium 
phosphate microparticles with the internal portion removed were studied 133. These 3D 
spherical substrates provide more space for cells to adhere and proliferate than on the 
conventional filled microspheres.  
Previously its was demonstrated that microcarriers support MSCs growth in the 
3D matrix, by allowing cell adhesion and proliferation. However, in order to be further 
applied as injectable systems, an adequate vehicle is required to deliver the cell-loaded 
microcarriers into the defect and to keep them in place. For example, Lippens and 
coworkers successfully injected MSCs-loaded gelatin-based (CultiSpher-S) carriers 
within a chemically modified form of a polyoxythylene-polyoxypropylene copolymer 
based hydrogel (under the tradename of Pluronic F127) and implanted the system in 
noncritical size unicortical defects, resulting in a faster bone repair 134. Oliveira et al. 
studied, different polymeric solutions as injectable matrices able to carry hydroxyapatite 
microspheres through an orthopedic device during an injection procedure: sodium 
carboxymethylcellulose, hydroxypropylmethylcellulose and Na-alginate 129, 135. Alginate 
was the material that presented the best performance. 
Overall, 3D microcarriers present advantages for application in tissue engineering 
because of their unique properties of scaling up 3D cell culture and loading capacity for 
drugs, growth factors or/and cells 121. Biocompatible microcarriers loaded with cells 
offer the advantage of being able to readily place a large number of cells directly (in 
situ) and controllably in an injectable way 136. Furthermore, microcarriers may also 
provide more than structural support for cells since they may work as regulators of cell 
function, metabolism and differentiation 137. 
 
 
Chapter I 
 
 
 25 
3.2.2. Microspheres for cell immobilization 
 
Traditionally, cell immobilization, or encapsulation as it is often called, consists in 
physically protecting a cell mass from an outside environment within the confines of a 
semipermeable membrane that is designed to circumvent immune rejection and also 
protect the cells from mechanical stress (Fig. 6) 138. This immune protection will 
eliminate or reduce the use of long-term therapies of modulating and/or 
immunosuppressive agents, which have potentially severe side-effects 116. To ensure 
cell survival, the membrane confining the cells needs to be permeable to nutrients and 
molecules diffusion (oxygen and growth factors) and allow the elimination of cell 
secretions and catabolic products, while keeping components of the immune system 
out 116, 139. Most of the research and applications in this field rely on the 
immunoprotective role of encapsulation technologies. The most widely used systems 
for that purpose consists in hollow polymeric systems (e.g. microcapsules) in which the 
active component is the polymeric selective membrane and the bulk of the system is 
filled with liquid. 
 
  
Figure 6. Cell immobilization technology consists in immobilizing cells within a polymeric 
semipermeable membrane (in this case, the bulk of the system is liquid) that is designed to 
circumvent immune reactions. The matrix allows the bi-directional diffusion of nutrients, oxygen, 
waste and the catabolic products 138. 
 
 
Although extremely promising, there are several challenges to overcome for the 
application of cell immobilization technology: lack of adequate clinical-grade polymers, 
production of uniform microspheres, use of polycations, forethoughts before 
transplantation (assessment of the exact dosage and molecular-weight cutoff), 
selection of the suitable cell types for immobilization (appropriate cell source), 
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transplantation site, regulatory and ethical issues 140. Moreover, to achieve a consistent 
clinical success critical aspects need to be taken into consideration: biocompatible, 
mechanically and chemically stable polymers with a suitable permeability providing 
immune protection; functional performance (allow the paracrine interaction between the 
cells within the microsphere and the host environment); biosafety; long-term cell 
survival (includes adhesion, proliferation and differentiation) and long-term survival of 
the graft (allow cell integration and consequently tissue repair) 116, 140. 
One consideration of primary importance for cell immobilization technology to 
succeed is the source of the matrix material. Since, for cell immobilization strategies, 
scaffolds must be formed under mild and cytocompatible conditions, the number of 
suitable materials and formulation are significantly limited 141. For that reason, the 
majority of biomaterials used in microsphere formation are hydrogels. Hydrogels offer 
unique characteristics for the designing of a suitable environment, providing a 3D 
structural support for cells and also a variety of biological cues that allow the 
maintenance of normal cellular functions 141-143. Different natural polymeric hydrogel-
based materials are available for cell immobilization and the most frequently used are 
agarose, alginate, collagen, fibrin, gelatin and hyaluronic acid 142. Nevertheless, other 
polymers have been applied for the production of microspheres: polyelectrolytes of 
anionic nature (cellulose sulfate, chondroitin sulfate, polyacrylic acid), cationic nature 
(poly-L-lysine, poly-L-ornithine, chitosan, poly(methylene-co-guanidine), 
polyvinylamine) as well as non-anionic polymers (polyvinyl alcohol, poly(hydroxyethyl 
methacrylate-co-methyl methacrylate), polyethylene glycol) 139. More recently several 
synthetic-based hydrogels have been produced, which include natural polymers that 
have been modified or synthetically built. These biomaterials can be organized into 
three categories: i) naturally derived hydrogels (DNA-based hydrogels, protein-based 
gels, polysaccharide-based gels, synthetic ECM analogs); ii) synthetic hydrogels 
(polyethylene glicol-based hydrogels, polyfumarate-based hydrogels, phosphoesters); 
iii) and biomimetic hydrogels (incorporation of proteins or small oligopeptides) 141. 
Noteworthy, among the above-cited materials, alginate is the most dominantly 
used (Fig. 7). Alginate is a natural polymer that is commonly applied in many tissue 
engineering applications due to its biocompatibility, low toxicity, relatively low cost and 
mild gelation behavior using divalent cations 144-147. 
The more recent cell immobilization strategies for tissue regeneration purposes 
differ significantly from previous strategies aiming at immunoprotection. 
Immunoisolation is no longer required since the systems are usually designed to 
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degrade in vivo, and be replaced by newly formed tissue. Also, tissue engineering 
strategies require adequate cell support for cell attachment, proliferation and 
differentiation and hence usually 3D polymeric systems are used instead of 
semipermeable membranes. 
 
 
Figure 7. A) Structure of alginate showing both β-D-mannuronic acid (M) and α-L-guluronic acid 
(G) monomers. Alginate is a natural biopolymer extracted from brown algae. Alginate polymers 
are a family of linear unbranched polysaccharides containing different amounts of G and M 
units, which may constitute a homopolymeric block (M block or G block) or a heteropolymeric 
block (M and G blocks). B) Alginate can be ionically crosslinked by the addition of divalent 
cations in aqueous solution, such as calcium (Ca2+) that exchange with the sodium ions from 
the guluronic units. The stacking of these G groups gives origin to the characteristic egg-box 
structure 148. 
 
 
Cell delivery using microspheres for tissue engineering applications has been 
explored in several works aiming MSCs transplantation and/or bone regeneration. 
Alginate has been the polymer most widely investigated for that purpose. Although 
being originally a non cell-interactive polymer, alginate can be covalently modified to 
promote cell adhesion through the incorporation of peptides containing the amino acid 
sequence arginine-glycine-aspartic acid (Arg-Gly-Asp, RGD) 149, 150. Evangelista 
demonstrated that RGD-modified alginate hydrogel, in contrast with unmodified 
alginate, was able to promote a much higher level of metabolic activity, adhesion and 
differentiation of immobilized MC3T3-E1 pre-osteoblastic cells 149. Moreover, its 
molecular weight can be modified through irradiation and oxidation to modulate its 
viscoelastic properties, as well as its degradation rate 150-152. The lower viscosity of the 
irradiated polymer results in reduced shear forces during the cell-polymer mixing 
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process and, consequently, in higher cell viability 153. Markusen et al. encapsulated 
MSCs in alginate beads covalently modified with RGD peptides with a sustained 
viability (>80%), but they did not observe cell proliferation during the two weeks 
experience 154. Also, Grellier et al. explored the ability of this matrix to promote bone 
tissue regeneration in vivo after immobilization of human osteoprogenitors combined 
with endothelial cells 71. Moreover, human mesenchymal progenitor cells from bone 
marrow were successfully immobilized within Ca-alginate microspheres and were also 
able to differentiate along the chondrogenic lineage 155. Alternatively, Zhang and 
colleagues have generated small cell-loaded alginate microspheres (~100 µm), with 
good morphology and high cell-loading efficiency, using the electrostatic spray method 
156. Later they studied the effect of rapid cryopreservation of this cell-loaded alginate 
system to achieve readily available constructs. They concluded that water in these 
small capsules vitrified leading to intact capsules after cryopreservation, showing that 
this process could be applied in cells that are sensitive to freezing and high 
cryoprotectants 157. Small microspheres (30-60 µm) were also produced using an 
alginate-barium system based on atomization processes that allow the administration 
of these microcapsules via injection and aerosol 158. 
Alginate, which is negatively charged, can also be combined with positively-
charged polymers, such as polylysine or chitosan, to prepare more stable 
microspheres. MSCs isolated from adipose tissue have been recently immobilized 
within an alginate-calcium core that was later complexed with chitosan and further 
cross-linked with genipin to increase the capsular strength 159. MSCs within this matrix 
were able to promote increased VEGF expression and endothelial cell growth when 
cultured with the conditioned medium from the encapsulated MSCs, showing the 
angiogenic potential of this system. In another work, MSCs were immobilized in 
alginate-polylysine microspheres for long periods (70 days) maintaining their 
mesenchymal surface markers, viability and the capability to differentiate into all three 
mesodermal lineages 160. Noteworthy, in vivo immobilized MSCs are significantly 
hypoimmunogenic and, since these cells have immunosuppressive properties, a semi-
permeable membrane may not be necessary 55, 56. Trouche and co-workers optimized 
MSCs delivery in alginate microspheres with and without a semipermeable membrane 
of polylysine and reported a higher viability of MSCs within microspheres without the 
semipermeable membrane 161. However, when non-autologous MSCs are used, a 
protective membrane may be advantageous for immunoisolation. Ding et al. used 
alginate-poly-L-lysine microcapsules to immobilize BMP-2 gene-transfected MSCs that 
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were shown to be capable of constitutive synthesis and of delivering biologically active 
BMP-2 protein, and thus with potential utility for bone regeneration 162. 
As previously pointed out, although alginate is the most widely used biomaterial 
for this purpose, there are other polymers that have been investigated for MSC 
immobilization. Agarose spheres containing immobilized matrix molecules (fibronectin 
and fibrinogen) that mediate cell-matrix interaction, allowed the survival of transplanted 
MSCs 163. Self-assembled collagen microspheres were able to provide a protective, 
growth- and migration-supporting matrix to MSCs 164. Gelatin microspheres were 
studied as temporary encapsulation system to protect marrow stromal osteoblasts from 
short-term environment effects caused by an injectable carrier (poly(propylene 
fumarate) 165. Preosteoblast within pectin microspheres were investigated as an 
injectable biomaterial for bone tissue engineering 166. Within this matrix cells maintain 
their viability, metabolic activity and differentiation capacity. 
MSCs were also successfully photoencapsulated in poly(ethylene glycol) (PEG) 
incorporating the RGD sequence and were able to differentiate into the osteogenic 
lineage in the presence of dexamethasone released from PEG capsules 167 168. It is 
also possible to obtain individually preserved nanoencapsulated MSCs by polyectrolyte 
layers of poly-L-lysine and hyaluronic acid using the electrostatic layer-by-layer 
assembly technique, due to its mild conditions, nanoscale precision, tenability and the 
ability to modify surface characteristics 169. 
Based on the previous examples, for bone tissue engineering applications 
microspheres present promising results. In general, this system allows cell survival, 
adhesion, proliferation and differentiation. Other advantage of this technology relies in 
the protection against shear stress and in avoiding cell loss by uncontrolled cell 
migration 155. The 3D polymeric system should be permeable to paracrine interaction 
between the cells within the microsphere and the cells from host environment. By 
changing parameters associated with the cell immobilization system, such as size, the 
performance of the microspheres can be easily improved in terms of nutrients and 
oxygen supply. Furthermore, the number and location of injected cells can be easily 
controlled through the number of microspheres administrated and their site of injection 
160. 
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3.2.3. In situ gelling biomaterials for cell entrapment 
 
The development of biomaterials with the capacity to be transformed from liquid 
to solid in situ under mild conditions creates new possibilities in bone tissue 
engineering. Moreover, the conjugation of these matrices with cells and biomimetic 
peptides represents significant advances in tissue engineering strategies. 
Recently, Low and co-workers reviewed the progress made towards the 
development of injectable calcium phosphate cements (CPCs) 114. These compounds 
can be applied as granules, blocks, hydraulic cements or as injectable pastes, and 
encompass several ideal properties, such as nontoxicity, biocompatibility and 
bioactivity 114. For instance, these cements have been used for augmentation of 
fractures involving crushed cancellous or osteoporotic bone, for bone defect filling or 
for gap filling around metal implants 170, 171. As it is injected, the cement interdigitates 
with adjacent bone and forms a solid structure. CPCs have also been studied in vitro 
and in vivo and also in small clinical studies for vertebroplasty, as an alternative for the 
most widely used bone void filler – the polymethyl methacrylate (PMMA) cement 172. To 
enhance the performance and expand the use of CPCs, research has been carried out 
to reinforce this compound with other materials, like fibers and polymeric additives 114. 
The natural polymer chitosan can be incorporated into CPCs yielding higher flexural 
strength, toughness and strain to failure 173. The CPC powder is mixed with the 
chitosan liquid and forms a paste that can be surgically applied via minimally invasive 
techniques and becoming a scaffold in situ. Moreau and colleagues investigated this 
strategy for MSCs delivery, and they were able to demonstrate that CPC-chitosan 
supports MSC attachment, proliferation and differentiation into the osteogenic lineage 
174. 
In the last few years, the concept of molecular self-assembly of peptides has lead 
to the development of new injectable biomaterials with potential in the field of bone 
tissue engineering 175, 176. After injection, these peptides self-assemble to form 
micrometer-long nanofibrils and these fibrils give rise to dynamic 3D scaffold gels 177. 
These designer self-assembling peptide nanofibers have been shown to be an 
excellent biological material for 3D cell cultures and to be capable of stimulating cell 
migration into the scaffold 178. Ozeki and co-authors suggested that the RAD16 (16 
amino acids sequence; also called PuraMatrix) could be used as a matrix for 
osteogenic differentiation of bone marrow stromal cells in vitro and in vivo 179. In other 
works using the same material, it was shown that MSCs could differentiate into mature 
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osteoblasts, to form mineralized matrices and to promote bone regeneration in the 3D 
structure 180, 181.  
Hydrogels present great potential as in situ injectable biomaterials for cell delivery 
143. The polymeric network mimics many features of the extracellular matrix and can be 
formed in situ by either chemical or physical crosslinking methods 182, 183. The structural 
integrity of hydrogels depends on crosslinks between polymer chains via various 
chemical bonds and physical interactions that are responsible for the formation of a gel 
184. The gelation reaction leads to the formation of a 3D network that is often 
employable as an injectable system where cells suspended in a liquid precursor 
solution are delivered in vivo to the site of interest in a minimally invasive way 141. For 
example, Wang and colleagues developed a thermosensitive hydrogel composite that 
is injectable at low temperature, with a rapid gelling period, and is capable of releasing 
insulin-like growth factor and support MSCs adhesion and growth 185. Another 
thermosensitive hydrogel based on poly(organophosphazene)-RGD conjugate mixed 
with MSCs was able to enhance bone formation in a nude mice model 186. Klouda et al. 
developed a thermoresponsive, in situ crosslinkable hydrogel based on N-
isopropylacrylamide that maintained MSCs viability for over 3 weeks and allowed 
osteogenic differentiation 187. Poly(propylene fumarate-co-ethylene glycol) based 
hydrogels modified in bulk with a covalently linked RGDS peptide allowed the adhesion 
and proliferation of marrow-derived osteoblasts 188. 
In an alternative hydrogel strategy, Fonseca and co-workers developed a 
sophisticated 3D cell culture microenvironment of modified alginate through partial 
crosslinking with a matrix metalloproteinase (MMP) cleavable peptide (proline-valine-
glycine-leucine-isoleucine-glycine, PVGLIG) combined with RGD peptides and used it 
in the preparation of injectable, in situ crosslinkable hydrogel-like matrices (Fig. 8) 189. 
MSCs were successfully immobilized within this matrix and shown to be capable of 
forming cellular networks. 
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Figure 8.  Schematic representation of functionalized alginate preparation and cell-hydrogel 
interactions: (A) soluble Na-alginate chains; (B) alginate chemically modified with cell-adhesion 
(RGD) and MMP-sensitive (PVGLIG) peptides; (C) crosslinking of alginate chains with calcium 
ions; (D) 3D culture of MSC within modified-alginate hydrogels; (E) integrin-mediated cell 
adhesion to RGD motifs present in the matrix; (F) cleavage of MMPs-sensitive peptide 
crosslinks by cellular proteases; (G) entrapped cells create pathways within the hydrogel, 
becoming less constrained, interacting with the matrix and surrounding cells 189. 
 
 
The development of in situ gelling systems has received large attention over the 
past decade. More importantly, an increased number of in situ gel forming systems 
have been investigated for tissue engineering 190. The interest has been sparked by the 
advantages shown by these in situ forming polymeric delivery systems, such as ease 
of administration, improved patient compliance and comfort. Moreover, they are also 
attractive for use in sterile conditions due to their reduced invasiveness associated with 
application. In addition, in situ cell immobilization is also beneficial for filling an irregular 
defect. 
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4. AIMS & OUTLINE OF THE THESIS 
 
Aims 
 
In this thesis, the putative crosstalk between mesenchymal stem cells (MSCs) 
and endothelial cells (ECs), key partakers in bone regeneration, was explored in the 
framework of a bone tissue engineering strategy.  
The first aim consisted in investigating whether a coculture system of MSCs and 
ECs (human umbilical vein endothelial cells, HUVEC) could modulate the phenotype 
and proliferation of harvested MSCs. Complementing previous studies, different 
relative cell ratios were analyzed for longer, therapeutically relevant, culture periods in 
the work herein described. Moreover, MSCs osteogenic commitment, morphology, 
metabolic activity and gene expression of some osteogenic markers were assessed as 
well.  
Secondly, a delivery system for MSCs based on alginate coupled with the 
arginine-glycine-aspartic acid (RGD) peptide, using a binary composition of high and 
low molecular weight alginate, was explored. To scrutinize the behavior of immobilized 
cells several parameters were considered, namely: metabolic activity, viability, 
morphology and osteogenic differentiation. Furthermore, it was evaluated whether and 
how MSCs immobilized in such 3D matrix influence the ability of neighboring ECs to 
form tube-like structures 
Finally, the in vitro potential of the injectable RGD-alginate hydrogel as an in situ 
forming matrix to deliver ECs was studied. Multiple experimental approaches were 
employed to investigate how this microenvironment could influence the behavior of 
vascular cells, namely their ability to promote the outward migration of viable and 
proliferative cells, whose capacity to form 3D arrangements is preserved  
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Outline of the Thesis 
 
One of the most promising tissue engineering approaches for the repair and 
regeneration of bone defects relies on the in vitro culture of three dimensional (3D) 
scaffolding materials seeded with autologous cells, followed by implantation into the 
patient 22, 191, 192. Displaying multiple attractive features, such as easy accessibility, 
expansion potential, immunosuppressive properties, paracrine-mediated effect and 
capacity to differentiate into bone forming cells (osteoblasts) mesenchymal stem cells 
are often the selected cell population for such biomaterial-based approach 37, 108, 193, 194, 
Essentially, MSCs’ fate decision can be regulated by several elements, including 
exogenous soluble growth factors, cytokines, hormones and chemicals, external 
mechanical forces and direct contact with other mature cell population 195, 196. As 
pointed out in section 2.2 of the general introduction, endothelial cells (ECs) have been 
shown to express factors that induce osteogenic differentiation in vitro, when in direct 
contact with bone marrow stromal cells 73, 77. However, this dialogue could influence not 
only the state of MSC differentiation, but also MSC proliferation. Intending to shed light 
on this issue, in Chapter II it was investigated if a synergistic coculture system of 
MSCs and ECs could affect the number and differentiation state of harvested MSCs. In 
contrast to other reports on this topic, the present investigation was carried out for a 
longer period of time (3 weeks instead of 1 to 6 days), and varying ratios of both cell 
types were considered 70, 72, 73, 78-81, 92, 197. Additionally, several media were tested and 
MSCs osteogenic commitment in a non-osteogenic medium in the presence of ECs 
was carefully analyzed. 
The success of biomaterials-based strategies is largely dependent on the 
success of the cell-material interface. The ability to functionalize a bioinert material like 
alginate with biomimetic peptides (integrin-binding arginine-glycine-aspartic acid (RGD) 
sequence) found in many extracellular matrix proteins, is sufficient to transform this 
polysaccharide into a material supporting cell adhesion, proliferation and organization 
149, 150. As highlighted in section 3 of the introduction, hydrogels represent an important 
class of biomaterials in biotechnology and medicine due to their excellent 
biocompatibility and minimum inflammatory response 198. Moreover, these hydrophilic 
polymeric networks provide a 3D support for cells, mimicking many features of 
extracellular matrix and can be used for cell immobilization under mild conditions (e.g., 
in alginate microspheres) or as in situ gelling biomaterials for cell delivery 144-146, 182, 183. 
Chapter III characterizes in detail the viability, metabolic activity and osteogenic 
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potential of MSCs immobilized within RGD-alginate microspheres and cultured under 
basal and osteogenic induction conditions.  
The capacity of a biomaterial scaffold to allow proper vascularization and, 
therefore, vascular cell survival and organization, is of paramount importance to its 
good performance. In Chapter III the ability of MSCs immobilized within RGD-alginate 
microspheres to influence angiogenesis was also investigated. Immobilized MSCs 
significantly enhanced the ability of neighboring ECs to form tube-like structures in a 
reconstituted basement membrane (Matrigel). Since the two cell types were not in 
direct contact, the presence of vascular endothelial growth factor (VEGF) in the culture 
medium was also assessed, to verify if MSCs were able to produce this signaling 
protein and if it was able to diffuse through the hydrogel network into the surrounding 
medium. 
Besides the strategies based on promoting angiogenesis from the host, in the 
past few years a growing interest has emerged in strategies for in vitro 
prevascularization of biomaterials 75, 76, 82, 85. Although vascularization remains an 
unsolved challenge in tissue engineering, encouraging developments have been made 
to grow and maintain, in vitro, these self-assembled biological vascular networks 108, 109. 
Polymers with the ability of forming 3D hydrogel networks offer an exciting possibility 
for the in situ delivery of vascular cells, allowing their organization into a 3D 
architecture and assisting cells in repopulating the surrounding tissue after 
transplantation 184. For example, an alginate matrix can be made from soluble 
precursor solutions that crosslink in situ, which allows its application at the injury site by 
minimally invasive methods 199. In Chapter IV the applicability of optimized injectable 
RGD-alginate hydrogels as vehicles for the minimally invasive delivery of endothelial 
cells was evaluated. Several techniques were employed to investigate the outcome of 
these microenvironments on vascular cell behavior, namely their ability to promote the 
outward migration of viable and proliferative cells that maintain the potential to form 
tubular-like structures. 
Finally, Chapter V provides concluding remarks, integrating insights from the 
preceding chapters and discusses promising avenues of future research. 
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ABSTRACT 
 
The purpose of this work was to investigate if a coculture system of human 
mesenchymal stem cells (hMSC) with endothelial cells (human umbilical vein 
endothelial cells, HUVEC) could modulate the phenotype and proliferation of harvested 
MSCs. In addition to previous investigations on the crosstalk between these two cell 
types, in the present work different relative cell ratios were analyzed for long, 
therapeutically relevant, culture periods. Moreover, MSCs osteogenic commitment was 
assessed in a non-osteogenic medium and in the presence of HUVECs through 
magnetic cell separation, cell quantification by flow cytometry, morphology by 
fluorescent microscopy, metabolic activity and gene expression of osteogenic markers. 
Collectively, the present findings demonstrate that, by coculturing MSCs with HUVECs, 
there was not only the promotion of osteogenic differentiation (and its enhancement, 
depending on the relative cell ratios used), but also a significant increase on MSCs 
proliferation. This augmentation in cell proliferation occurred independently of relative 
cell ratios, but was favored by higher relative amounts of HUVECs. Taken together, this 
data suggests that HUVECs not only modulate MSC phenotype but also their 
proliferation rate. Therefore, a coculture system of MSCs and HUVECs can a have a 
broad impact on bone tissue engineering approaches. 
 
 
Keywords: Cell-cell contact; Bone regeneration; Coculture; Osteogenic differentiation; 
Tissue engineering. 
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INTRODUCTION 
 
Mesenchymal stem cells (MSCs) represent an adherent, fibroblast-like population 
present not only in bone marrow, but also in a number of other tissues, including blood, 
adipose tissue, muscle and dermis 1. In bone tissue engineering approaches, bone 
marrow MSCs have demonstrated great potential for the treatment of bone loss, 
fracture non-union and osteogenesis imperfecta 2, 3. The success of bone regeneration 
strategies is in part based in the reintroduction of in vitro expanded cells in a state that 
guarantees their differentiation into functional bone matrix-producing cells 4. MSCs 
differentiated into the osteogenic lineage represent thus an appealing source of adult 
stem cells for bone tissue engineering applications 5.  
However, these approaches find limitations in the considerably low percentage of 
MSCs in adult bone marrow, and the vast numbers required for therapeutic approaches 
1, 6. The identification of mechanisms involved in stem cells self-renewal and 
differentiation is important for the design of new strategies to expand stem cells in vitro 
and modulate their phenotype. MSCs fate decision can be regulated by exogenous 
soluble growth factors, cytokines, hormones and chemicals and by external mechanical 
forces 7. Another approach to guide MSCs fate relies in the coculturing with other 
mature cell populations 8. Ball and co-authors demonstrated that MSC are profoundly 
influenced by other cell types in direct contact 8. Among these, endothelial cells (ECs) 
have been shown to express several factors, such as BMP-2, that induce osteogenic 
differentiation in vitro, when in direct contact with bone marrow stromal cells 9, 10. 
Moreover, Villars and colleagues (2002) showed that intercommunication between ECs 
and osteoblast-like cells is dependent not only on diffusible factors but also on gap 
junctions (connexin 43) that play a crucial role in cell differentiation, which points to the 
need of cell-cell contact 11, 12. Overall, two main dialogues were identified: a paracrine 
effect through VEGF, BMP-2, IGF production and a juxtacrine mechanism by gap 
junctional activity between the two cell types 13, 14. 
Although several works have been evaluating the influence of a number of 
parameters for large-scale production of MSCs, such as cell source, age, density, 
passage number, medium composition, presence of growth factors and serum choice, 
the concept of using cocultures for MSCs expansion, in particular with ECs, seems to 
constitute a promising approach for bone regeneration applications and is far from 
being completely investigated 1, 6, 15-19. 
The objective of this work was to investigate if a synergistic coculture system of 
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MSCs with endothelial cells could affect the number and state of differentiation of 
harvested MSCs. In contrast to other papers, in this cell-cell communication topic, the 
investigation was carried out for a longer time, 3 weeks instead of 1 to 6 days and 
different ratios of both cell types were considered 10-12, 20-25. Additionally, several media 
were tested and MSCs osteogenic commitment in a non-osteogenic medium in the 
presence of ECs was carefully analyzed. The present results demonstrated that, 
independently of the relative cell ratio used, the coculture system promotes a 
significant increase in MSCs proliferation and differentiation. Furthermore, these results 
indicate that, for tissue engineering applications requiring a large number of MSCs 
committed into the osteogenic lineage, a coculture system with endothelial cells could 
be advantageous. 
 
 
MATERIALS AND METHODS  
 
Cell cultures 
Human mesenchymal stem cells from bone marrow (MSCs, Lonza) were cultured 
and expanded in MSCGM (MSC growth medium, Lonza). For the experiments, cells 
were used at passage 8 and cultured in basal medium: Dulbecco’s modified Eagle 
medium with low glucose (DMEM, Gibco), supplemented with 10% v/v inactivated fetal 
bovine serum (FBS, Gibco) and 1% v/v penicillin/streptomycin (P/S, Gibco). The culture 
medium was changed every other day. 
Human umbilical vein endothelial cells (HUVECs, ScienCell) were cultured in 
M199 medium (Gibco), supplemented with 10% of inactivated fetal bovine serum (FBS) 
(Gibco), 0.1 mg/mL of heparin (Sigma) and 0.03 mg/mL of endothelial cell growth 
supplement (ECGS) (Sigma-Aldrich). HUVECs were used until passage 8 and 
harvested on 0.1 % w/v gelatin-coated tissue culture. The medium was renewed every 
2 to 3 days until the cells reached confluence. 
For cocultures, a pre-selection of the most adequate medium was performed. 
Several commercial media were tested, including Iscove Modified Dulbecco Medium 
(IMDM), M199, DMEM and a mixture 1:1 of these last two media. Cell behavior was 
analyzed in terms of metabolic activity and total protein content along the time. 
After medium selection, MSC and HUVEC monocultures were seeded at a 
density of 3x103 cells/cm2 and cultured for 21 days. For cocultures both cell types were 
seeded at 1.5x103 cells/ cm2 (1:1), resulting in a final cell density of 3x103 cells/cm2. For 
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all the studies the total initial cell density was of 3x103 cells/cm2. For control 
experiments MSCs monocultures were seeded with a lower cell density (1500 
cells/cm2, the same MSC density used in the cocultures). 
 
Cell metabolic activity 
To measure metabolic activity a resazurin-based assay was performed. This 
method is based on the conversion of resazurin to resorufin by metabolically active 
cells that result in the generation of a fluorescent product. At different time points the 
medium was removed from the wells and resazurin (Sigma) was added in fresh 
medium at a final concentration of 10% (v/v). Then, cells were incubated at 37ºC for 
4h, after which 200 µL/well were transferred to a 96 well black plate and fluorescence 
was measured (530 nmEx/590 nmEm) in a Spectra Max Gemini XS (Molecular Devices). 
 
Protein concentration 
The bicinchoninic acid protein assay (BCA, Pierce) was used to detect and 
quantify the total protein content, as recommended by the manufacturer. Briefly, three 
samples of cell lysates for each condition, obtained by brief sonication in ice with 1% 
v/v Trition X-100, were incubated with the bicinchoninic acid (BCA) working reagent for 
1 h at 37ºC. Then, the absorbance was read at 540 nm in a microplate reader (SLT 
Spectra). 
 
Effect of relative cell ratios on MSC behavior 
The effect of MSCs and HUVECs relative ratios on MSCs behavior was 
evaluated by testing the following cell combinations: 25%HUVEC-75%MSC, 
50%HUVEC-50%MSC and 75%HUVEC-25%MSC. MSCs monocultures were used as 
a control and were seeded at a cell density of 3x103 cells/cm2. Independently of the cell 
ratio, cocultures were also prepared at the same total density of 3x103 cells/cm2, and 
the percentage for each cell type was calculated with reference to that density. The 
studies were carried on for 21 days.  
To induce the formation of mineralized extracellular matrix, studies were 
performed in the presence of osteogenic stimuli (further on designated as osteogenic 
medium): basal medium (DMEM and M199 (1:1)) supplemented with 10 mM β-
glycerophosphate (Sigma), 10-8 M dexamethasone (Sigma) and 50 µg/mL ascorbic 
acid (Fluka).  
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Cell separation and quantification 
At different time points, cells were detached from the well plate and an aliquot of 
cell suspension was transferred to a Neubauer chamber for total cell counting. 
To quantify and further perform gene analysis on each cell type after coculture, 
cells were separated by magnetic cell sorting using magnetic beads coupled with an 
antibody against CD31 (Invitrogen) 12. For this purpose, cells in coculture were 
harvested by trypsin and then incubated with anti-CD31 magnetic beads (at a ratio of 
10:1 beads/HUVECs) for 30 min at 4ºC under gentle stirring. Afterwards, the 
supernatant fraction containing the cocultured MSCs (CoMSCs) was separated from 
the bead fraction, which contained the cocultured HUVECs (CoHUVECs), using a 
magnet device (Invitrogen). 
 
Cell morphology 
To analyze cell morphology, after fixation with 4% w/v paraformaldehyde and 
permeabilization with 0.1% v/v Triton X-100, cells were stained for F-actin (Alexa Fluor 
488 phalloidin; Molecular Probes) and for nuclei (4’,6-Diamidino-2-phenylindole 
dihydrochloride, DAPI; Sigma) and then visualized under an inverted fluorescence 
microscope (Axiovert 200M, Zeiss).  
 
Flow cytometry analysis 
Flow cytometry studies were performed on MSCs monocultures and on 
MSCs/HUVECs cocultures at different cell ratios. The percentage of HUVECs in the 
cocultures was estimated using anti-human CD31 (PECAM-1) antibody labeled with 
FITC (BD Biosciences). Cell suspensions were stained for 15 min, and for each day 
and ratio, 10,000 events were analyzed in triplicate on a FACSCalibur flow cytometer 
(Becton Dickenson). Data processing was performed using FlowJo software 8.7. 
 
Alkaline phosphatase (ALP) activity 
For ALP cytochemistry cells were incubated in the dark for 1h at 37ºC in Naphtol 
AS-MX phosphate/Fast Violet B salt (Sigma), as recommended by the manufacturer. 
After being rinsed with deionized water and air-dried samples were observed under an 
inverted microscope (Axiovert 200M, Zeiss). 
For quantitative ALP analyses, cell lysates were obtained by treatment with 1 % 
v/v Triton X-100 under brief sonication in ice, and then incubated with the chromogenic 
substrate 2 mM ρ–nitrophenol phosphate in 0.2 M bicarbonate buffer (pH 10), 0.05 % 
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v/v Triton X-100, and 4 mM MgCl2 (Sigma) for 1h at 37 ºC. The reaction was stopped 
by adding 1 M NaOH and absorbance was read at 405 nm in a microplate reader (SLT 
Spectra). The amount of product was obtained from a p-nitrophenol standard curve. 
The enzymatic activity was normalized to total protein concentration, obtained using 
the bicinchoninic acid protein assay (BCA, Pierce), and expressed as nmol/min/mg 
protein. 
 
Mineralization 
For assessment of mineralization by von Kossa staining cells were fixed with 
3.7% v/v formaldehyde in PBS during 15 min. Then, cells were incubated in 2.5 wt-% 
silver nitrate (Sigma) for 30 min under UV light, followed by incubation in 5 wt-% 
sodium thiosulfate (Aldrich) for 3 min. Finally, wells were rinsed with deionized water 
and air-dried prior to observation under an optical microscope. 
 
Phenotype analyses through mRNA expression 
Total RNA was extracted from MSCs in mono- and cocultures, at weekly time 
points, using the Total RNA isolation Kit (Macherey-Nagel), as recommended by the 
manufacturer. Subsequently, 1 µg of the total RNA was used as template for single 
strand cDNA synthesis with the Superscript pre-amplification system (Invitrogen) in a 
20 µL final volume containing 20mM Tris-HCl (pH 8.4), 50mM KCl, 5 mM MgCl2, 10 
mM DTT, 0.5 mM of each dATP, dCTP, dGTP and dTTP, 0.5 µg oligo(dT)12-18, and 
50 U of reverse transcriptase. After incubation at 42ºC for 50 min, the reaction was 
stopped at 70ºC for 15 min. After the cDNA synthesis reaction, qReal-Time PCR was 
carried out in a total volume of 25 µL of a mixture containing 5 µL of cDNA diluted at a 
1:80 ratio (corresponding to 3.125 ng of total RNA), 200 nM of each forward and 
reverse primers and 1x Mesa Green qPCR MaterMix Plus for Sybr Assay 
(Eurogentec). Primers of ubiquitary ribosomic protein P0 forward: 5 ´ 
ATGCCCAGGGAAGACAGGGC 3´; reverse: 5’ CCATCAGCACCACAGCCTTC 3´; 
type I collagen (COL I) forward: 5’ GGA ATG AGG AGA CTG GCA ACC 3´ and reverse 
5´ TCA GCA CCA CCG ATG TCC AAA 3´; alkaline phosphatase (ALP) forward 5´ AGC 
CCT TCA CTG CCA TCC TGT 3´; reverse 5´ ATT CTC TCG TTC ACC GCC CAC 3´; 
transcription factor Runx2 forward 5’ GTGCCTAGGCGCATTTCA 3’ and reverse 5’ 
GCTCTTCTTACTGAGAGTGGAAGG 3’; osteocalcin (OCN) forward 5’ 
TGAGAGCCCTCACACTCCTC 3’ and reverse 5’ ACCTTTGCTGGACTCTGCAC 3’; 
bone sialoprotein (BSP) forward 5’ CGATTTCCAGTTCAGGGCAGT 3’ and reverse 5’ 
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CAACACTGGG CTATGGAGAG G 3’. qRT-PCR experiments were run using an iQ5 
(Bio-Rad) and analyzed with the iCycler IQTM software. Relative quantification of gene 
amplification by qRT-PCR was performed using the cycle threshold (Ct) values and 
relative expression levels were calculated as follows: 2^(Ct P0gene - Ct gene of 
interest). The expression value for each target gene was normalized to the P0 value at 
each time point. Afterwards, the gene expression at each day was normalized to day 0. 
For each PCR, samples were analyzed in duplicate and three independent 
experiments were performed. 
 
Statistical analyses 
Statistical analyses were performed using SigmaStat (Statistical Software, 
STAT32 MFC Application). Statistical significance was assessed by using two way 
analysis of variance (ANOVA) in conjunction with Tukey’s test, pairwase multiple 
comparison procedures. Differences were considerer statistically significant when p 
values were lower than 0.05. All data are presented as mean values ± standard 
deviation. 
 
 
RESULTS 
 
Selection of base medium 
HUVECs and MSCs behavior was evaluated in several commercial media, 
including Iscove Modified Dulbecco Medium (IMDM), Medium 199 (M199), Dulbecco's 
Modified Eagle's medium (DMEM) and a mixture 1:1 of the last two media. The three 
media present some major differences in terms of composition, (composition provided 
by the manufacturer). For instance, IMDM and M199 have a higher number of amino 
acids than DMEM. IMDM has the highest glutamine concentration, followed by DMEM 
and then M199. Additionally, M199 has the lowest concentrations on vitamins and the 
other two have a similar composition. In the inorganic salts content, such as calcium, 
chlorine, iron, potassium, no major differences were found. Regarding other 
components, IMDM is the only with HEPES (5958 mg/L) and presents a D-Glucose 
concentration (4500 mg/L) higher than the others (1000 mg/L). Moreover, M199 does 
not have sodium pyruvate in its composition.  
To evaluate the effect of the different media on cell behavior, metabolic activity 
and protein quantification assays were carried out (Fig. 1). Overall, there was a 
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continuous increase in terms of the metabolic activity and protein content along the 
time, for both HUVECs and MSCs, in all the media tested. However, the medium that 
showed the best results was different in both cell types. Considering both assays, for 
HUVECs the following profile could be outlined: IMDM > M199 = M199+DMEM > 
DMEM. For MSCs the following sequence was obtained: M199+DMEM > DMEM > 
IMDM = M199. In a coculture approach, the selected medium should take into 
consideration the behavior of both cell types. Collectively, the described data pointed 
towards the selection of the combined medium M199+DMEM, which provided a 
performance close to the ideal in both situations.  
 
 
 
Figure 1. (A,B) Metabolic activity and (C,D) protein concentration of (A, C) human umbilical vein 
endothelial cells  and (B,D) mesenchymal stem cells cultured under four different media: M199, 
M199 with DMEM, DMEM and IMDM. The initial cell seeding density was the same in all the 
conditions (3x103 cells/cm2). Data are expressed as mean ± standard deviation (n=3). (* p ≤ 
0.05; ** p ≤ 0.01; *** p ≤ 0.001) 
 
 
 
Coculture study: cell quantification, morphology and differentiation 
Cocultures were established by seeding the two different cell types in direct 
contact at a cell ratio of 1:1. Both cell types were cultured (in mono- and coculture) in 
the selected medium, and the evolution on the number of total cells along the time was 
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analyzed, as depicted in Fig. 2. Cells in coculture exhibited, as a whole, a significant 
increase in number throughout the culture, reaching from day 14 values significantly 
higher than any of the monocultures, and continued to proliferate along the last week 
(Fig. 2A).  
When both cell types were analyzed in separate, it could be seen that while the 
number of MSCs in monoculture significantly increased until day 14th and then 
remained practically unchanged, the MSCs in coculture (CoMSCs) increased in 
number throughout the 21 days (Fig. 2C). Moreover, CoMSCs presented higher 
proliferation rate than MSC in monoculture (at 1.5 x103 or 3 x103 cells/cm2) in the last 
two weeks of culture. MSCs in coculture increased rapidly, reaching approximately 
80% of the cells in coculture after 1 week, and then cells continued to proliferate until 
the end of the culture, reaching a percentage of 94% (Fig. 2B).  
The HUVECs in monoculture showed higher proliferation rate than the MSCs on 
the 1st week of culture (Fig. 2A). However, the number of cells significantly decreased 
thereafter. Although the percentage of HUVECs in coculture (CoHUVECs) 
progressively declined, cells continued to proliferate during the 2nd week (Fig. 2D).  
 
 
 
Figure 2. Mesenchymal stem cells (MSC) and human umbilical vein endothelial cells (HUVEC) 
cultured in mono- and coculture during 21 days. (A) Total cell number of MSC, HUVEC and 
coculture of both cell types; (B) Relative number of MSC (CoMSC) and HUVEC (CoHUVEC) in 
the coculture; (C) Fold increase in cell number relative to day 0 of MSC in the coculture 
(CoMSC 1500; 1500 cells/cm2 of MSCs with 1500 cells/cm2 of HUVECs), MSC in monoculture 
with a cell density of 3000 cells/cm2 (MSC 3000), and MSC in monoculture with a cell density of 
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1500 cells/cm2 (MSC 1500); (D) Fold increase in cell number relative to day 0 of HUVEC in 
mono- and co-culture during 21 days. Cocultures were established by seeding the two cell types 
in direct contact at a cell ratio of 1:1 with a final cell seeding density of 3x103 cells/cm2 and the 
medium used (mixture 1:1 of DMEM and M199) was the same in all the conditions tested. For 
monocultures cell density was of 3x103 cells/cm2 with the exception of MSC 1500. Data are 
expressed as mean ± standard deviation (n=3). (* p ≤ 0.05; *** p ≤ 0.001) 
 
 
The cell morphology study, revealed evident differences between cells 
organization in MSCs mono- and cocultures, as can be depicted in Fig. 3A. MSCs in 
monoculture appeared randomly distributed at the cell culture surface along the first 2 
weeks, revealing, at day 21, a fibroblastic-like shape with stress fibers running in 
parallel according to cell orientation. In coculture, cells were rearranged in a 
significantly different manner, forming a kind of tubular-like cellular network. This type 
of structure becomes less evident along the time, as the cell density rose. At day 21, it 
was possible to visualize a crisscrossed pattern of actin cytoskeleton with thick stress 
fibers. 
Differences in cells morphology were also evident on the ALP cytochemical 
analysis (Fig. 3B). However, in cocultures it was possible to detect a much higher 
amount of ALP positive cells in all time points. For instance, at day 14, the wells from 
the coculture revealed an almost monochromatic (pink) surface. These results were 
further corroborated by the ALP colorimetric assay (Fig. 3C). ALP activity, normalized 
to total protein concentration, reached significantly higher levels in coculture than in 
monoculture. In monoculture the levels of ALP remained low and constant throughout 
the culture and always below the values reached in coculture. 
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Figure 3. (A) Immunocytochemistry of actin filaments (green) and nuclei (blue) and (B) ALP 
histochemistry and (C) ALP activity in MSCs cultured alone or cocultured with HUVECs at 
different time points under basal conditions. Cocultures were established by seeding the two 
different cell types together at a cell ratio of 1:1 with a final cell seeding density of 3x103 
cells/cm2. Bars correspond to 200 µm. Data are expressed as mean ± standard deviation (n=3). 
(* p ≤ 0.05; *** p ≤ 0.001) 
 
 
As previously described, the two types of cells in coculture were separated and 
additional differentiation studies were performed using only the MSC fraction. The gene 
expression profile of several osteogenic markers was analyzed (Fig. 4). The gene 
profile for ALP and COL I revealed a significant difference between MSC in 
monoculture and cocultured MSC (CoMSC) (for ALP p < 0.05 and for type I collagen p 
= 0.01). Runx 2 and BSP presented a significant increase after one week of culture in 
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CoMSC. The late-stage osteogenic differentiation marker, OCN, even after 21 days of 
culture did not show significant differences between MSC and CoMSC. 
 
 
 
Figure 4. Gene expression levels of osteogenic markers of mesenchymal stem cells (MSC) 
growing in monoculture and in coculture with endothelial cells (CoMSC) by qPCR. (A) type I 
collagen (COL I), (B) alkaline phosphatase (ALP) and (C) bone sialoprotein (BSP) and 
transcription factor Runx2 at day 7 and osteocalcin (OCN) at day 21. To perform gene analysis 
on CoMSC, cells were separated by magnetic cell sorting using magnetic beads coupled with 
an antibody against CD31. CoMSC presented significantly higher expression levels for COL I 
and ALP than MSCs in monoculture (collagen type I p = 0.01 and ALP p < 0.05). The 
experiment was performed three times, each in triplicate. (** p ≤ 0.01; *** p ≤ 0.001) 
 
 
Effect of different cell ratios on MSC behavior 
In order to evaluate the effect of MSCs and HUVECs relative ratios on MSCs 
behavior, the following combinations were tested: 25%HUVEC-75%MSC, 50%HUVEC-
50%MSC and 75%HUVEC-25%MSC. MSCs monocultures were used as a control. 
The influence of endothelial cells on the metabolic activity, proliferation and osteogenic 
differentiation of MSCs was analyzed. 
Concerning metabolic activity (Fig. 5A), the three different ratios presented a 
significant increase along the first 2 weeks of culture, followed by a plateau, although 
the MSC monoculture showed the highest fold increase after 1 week. During the 2nd 
and 3rd weeks this behavior changed, and cells in coculture reached metabolic activity 
values significantly higher than the monoculture, at all the ratios tested. Among the 
different ratios, the combination 50%HUVEC-50%MSC was the one that presented the 
highest increase, although not significantly different from the others. 
The evolution of the number of cells along the time is depicted in Fig. 5B, 
showing that in all the three ratios tested, the percentage of MSCs increased, while the 
relative amount of HUVECs decreased. In fact, MSCs were able to proliferate 
throughout the 21 days of culture and the ratio that showed the highest MSCs 
proliferation was the one that started with a lower percentage of MSCs (75%HUVEC-
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25%MSC). Moreover, in this ratio, HUVECs presented the lowest decline. 
 
 
 
Figure 5. (A) Metabolic activity, relative to day 1, of mesenchymal stem cells (MSC) in 
monoculture or in coculture with human umbilical vein endothelial cells (HUVEC) and (B) the 
percentage of both cell types in the coculture during 21 days. Cocultures were tested using 
different relative cell ratios: 25% HUVEC with 75% MSC (25EC:75MSC), 50%HUVEC with 50% 
MSC (50EC:50MSC) and 75% HUVEC with 25% MSC (75EC:25MSC). Independently of the 
cell ratio, cocultures have also the same final density of 3x103 cells/cm2. Thus, the used 
percentage for each cell type in the coculture was related to this final value of 3x103 cells/cm2. 
Metabolic activity was assessed using the resazurin-based assay and relative quantification 
was obtained by flow cytometry. Data are expressed as mean ± standard deviation (n=3). 
 
 
To analyze MSCs differentiation in the coculture systems, ALP activity was 
measured weekly for a 3 weeks period, as illustrated in Fig. 6. Under basal conditions 
(Fig. 6A), MSCs in monoculture kept a similar low value (practically null) throughout the 
time, without significant variations. However, in the presence of HUVECs, there was an 
increase on the ALP activity. Although the cocultures showed the highest values, only 
in the last week they reached values significantly higher than those obtained in 
monoculture. The ratios 25%HUVEC-75%MSC and 50%EC-50%MSC were the ones 
resulting in the highest ALP activity values. Under osteogenic conditions, MSCs 
monoculture showed a significant increase on ALP activity during the 1st week 
reaching then a plateau (Fig. 6B). In general, in the first 2 weeks of culture, the three 
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relative ratios tested did not present significant ALP differences between them. In the 
last week there was a significant upregulation in ALP activity in all the cocultures, with 
values significantly higher than the MSCs monoculture.  
When comparing osteogenic with basal conditions, ALP activity values were not 
very different but were in general slightly higher in the former. Additionally, all the ratios 
tested achieved significantly higher ALP activity values than the monoculture. 
Cytochemical stainings of ALP activity and mineralization nodules are presented 
in Fig. 7, and provide additional qualitative evidence that cells differentiated along the 
osteoblastic lineages at all ratios tested.  
 
 
 
Figure 6. Alkaline phosphatase activity of mesenchymal stem cells (MSC) cultured alone or 
cocultured with human umbilical vein endothelial cells (HUVEC) at different relative cell ratios 
under (A) basal conditions and (B) osteogenic conditions. Results are expressed in nmol per 
min per mg of protein. Cocultures were tested at different relative cell ratios: 25% HUVEC with 
75% MSC (25EC:75MSC), 50% HUVEC with 50% MSC (50EC:50MSC) and 75% HUVEC with 
25% MSC (75EC:25MSC). Independently of the cell ratio cocultures were also prepared at a 
total density of 3x103 cells/cm2, and the percentage for each cell type was calculated with 
reference to that density. Data are expressed as mean ± standard deviation (n=3). (* p ≤ 0.05; 
** p ≤ 0.01; *** p ≤ 0.001) 
 
 
Chapter II 
 
 
 
 69 
 
Figure 7. Alkaline phosphatase activity (ALP) and von Kossa (vK) histochemistry in cocultures 
after 21 days, under basal conditions (BC) and osteogenic conditions (OC). Cocultures were 
tested at different relative cell ratios: 25% HUVEC with 75% MSC (25EC:75MSC), 50% HUVEC 
with 50% MSC (50EC:50MSC) and 75% HUVEC with 25% MSC (75EC:25MSC). Independently 
of the cell ratio cocultures were also prepared at a total density of 3x103 cells/cm2, and the 
percentage for each cell type was calculated with reference to that density. Bars correspond to 
200 µm. 
 
 
DISCUSSION 
 
A large number of MSCs committed to the osteogenic lineage is necessary for 
creating a tissue-engineered implant able to fill bone defects. It is generally accepted 
that MSCs play a critical role in bone tissue regeneration due to their differentiation 
capacity into distinct end-stage cell types, immunosuppressive properties and ability to 
produce a broad spectrum of bioactive macromolecules that are capable of 
establishing a regenerative microenvironment 26. In bone marrow, MSCs represent a 
very small fraction of all nucleated cells: less than 0.01% 27, 28.  
As previously pointed out, this study focused on the use of a MSCs-endothelial 
cells coculture system as a strategy to modulate MSCs expansion and osteogenic 
differentiation in vitro. Our team is specifically interested in addressing this subject in 
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the context of a minimally invasive bone regeneration strategy using injectable 3D 
matrices 29-33. As reviewed by Grellier and colleagues (2009) there are some studies on 
the reciprocal regulation and functional relationship between bone and endothelial cells 
which, in turn, may be greatly influenced by the culture conditions 13.  
In a preliminary phase of the present study, and due to its impact in future cell 
studies, the appropriate medium for the coculture system was established. It is worth 
mentioning that, due to the dramatic influence that the batch of serum may have on 
MSCs behavior at different levels (proliferation, differentiation and gene expression) 6, 
a previous serum batch-selection was made and it was used to supplement all the 
tested media. Media selection was based on cell metabolic activity, total protein 
content and optical microscopy analyzes (Fig. 1). The tested media included those 
routinely used to culture the two cell types in monoculture (DMEM and M199 for MSCs 
and HUVECs, respectively) and also IMDM, a medium reported in several works for 
expansion and further coculture of both cell types 10, 12, 20, 24, 34, 35. In several other 
studies, the medium selected for the cocultures was the same one used for ECs 
monocultures 21-23, 36-42. Here, the medium selected was a DMEM+M199 mixture (1:1). 
After one week of culture, the cell performance in the presence of this medium was 
closer to the one obtained with DMEM and M199 for MSCs and HUVECs, respectively. 
Moreover, by choosing this mixed medium, cells in coculture will continue to be in 
contact with their expansion medium.  
Several published studies on this topic provide insights into the relationship 
between the two cell types but there is still a limited knowledge concerning the 
proliferation behavior of cells in coculture. For a detailed analysis on cell proliferation in 
coculture, immunomagnetic beads coupled with an anti-CD31 antibody were used to 
separate both cell types. This technique allowed confirming that both cell types were 
proliferating, although with significantly different growth rates, being it higher for MSCs. 
This difference in cell proliferation could explain the different percentage of both cell 
types in coculture (Fig. 2). Moreover, MSCs growing in coculture (CoMSC) showed a 
clearly higher cell growth rate as compared with MSCs in monolayer. On one hand, this 
result points towards the potential of HUVECs to stimulate MSCs proliferation. On the 
other hand, MSCs could curtail ECs capability for expansion due to their high 
proliferative capacity in coculture. Notwithstanding that HUVECs in monoculture 
presented a higher growth rate than in coculture, CoHUVECs proliferated for a longer 
period than HUVECs alone. This ruled out the possibility that CoHUVECs may be 
dying since, in fact, there was an increases in cell number. Noteworthy, in monoculture 
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when endothelial cells are maintained at confluence for an extended period of time, 
they become tightly packed but show no tendency to overlap or overgrow. Then, when 
cell density becomes to high, cells start to detach and die 43. 
Another parameter that could influence cell proliferation was the extracellular 
matrix produced, since an increase on one of its major components was detected 
(upregulation of collagen type I). In parallel, a study was perform to validate that the 
significant increase in CoMSC proliferation was indeed related with HUVECs presence, 
and not with differences in terms of cell seeding densities (CoMSCs cell seeding 
density was 1500 cells/cm2 instead of 3000 cells/cm2 as the MSC monoculture). For 
that purpose MSCs were seeded alone at 1500 cells/cm2, which allow comparing with 
CoMSC of the same real “age” (having gone through the same cell divisions) during 
the 21 days of culture (Fig. 2C). Although MSCs at lower cell density presented a 
higher proliferation rate in the first weak, in the following two weeks CoMSCs continued 
to exhibit the highest proliferation (Fig. 2C), corroborating the potential of HUVECs to 
stimulate MSCs proliferation. 
It is well established that the cytoskeleton plays important roles in cell 
morphology, adhesion, growth and signaling. The actin network, one of the three 
components of the cytoskeleton, is of critical importance in the determination of the 
mechanical properties of living cells. In this study, it was shown that the actin 
cytoskeleton changes from an apparently well-organized structure, with long fine fibers 
running in parallel along the cell axis in MSCs monocultures, to a more random 
arrangement of the actin cytoskeleton in cocultures (Fig. 3A). Yourek and colleagues 
observed this type of cytoskeleton changes upon osteogenic differentiation 44. They 
further stated that this reorganization could be related with the natural reaction of the 
actin cytoskeleton in bone cells to the shear stress that occurs in vivo during bone 
modeling/remodeling. Grellier et al. (2009) also observed a similar cell rearrangement 
in osteoprogenitor cells (HOPs) cocultured with ECs 12. They further observed HUVECs 
migration along HOPs and suggested that the direct contact between the two cell types 
could stimulate the release of chemotactic factors that, in turn, would stimulate HUVEC 
migration. 
To support the hypothesis that cytoskeleton changes of CoMSC could be related 
with their osteogenic differentiation in the presence of endothelial cells, further studies 
were made. Consequently, ALP cytochemistry and activity, and also gene expression 
analyzes of osteogenic markers, were performed. ALP activity is considered an early 
osteogenic marker since its expression increases from the beginning of cell 
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differentiation and increases throughout extracellular matrix maturation 45. As shown in 
Fig. 3B there was an increased in the number of ALP stained cells in coculture 
comparing to monoculture even after only 3 days, suggesting a commitment of 
CoMSCs into the osteogenic lineage. The ALP activity profiles and gene expression 
were assessed and both support the previous data (Figs. 3C and 4B). The gene profile 
of type I collagen, a protein of the extracellular matrix and the main organic component 
of bone tissue, was also higher in CoMSC (Fig. 4A). In order to further analyze 
osteogenic commitment of CoMSC, gene expression of two other early markers of 
osteogenic differentiation, Runx2 and bone sialoprotein (BSP), was evaluated by real 
time quantitative RT-PCR assay. Runx2, is an earlier transcription factor proven 
essential for commitment to osteoblatogenesis. BSP is a major non-collagenous 
extracellular matrix protein in bone and promotes the initial formation of mineral 
crystals 46, 47. Both genes were significantly upregulated, which further confirms the 
differentiation of CoMSC along the osteoblastic lineage (Fig. 4C). Other gene that was 
investigated was osteocalcin (OCN) that is a noncollagenous calcium-binding bone 
protein and is considered a late-stage osteogenic differentiation marker 48. OCN 
expression did not increase and, even after 21 days, there was no upregulation. 
Overall, the genetic profile obtained points towards an osteogenic commitment of 
MSCs culture in the presence of ECs, but cells were not fully mature. 
The effect of the relative HUVECs-MSCs ratio was also investigated. This aspect 
can be controversial since many different combinations were found in the literature: 4:1 
39, 2:1 10, 12, 20, 30, 35, 49, 1:1 4, 9, 21-23, 36, 38, 50, 51, 1:1.5 37, 6.5:1 41, 3:1 24, 1.5:1 52 of 
endothelial and osteoblast-like cells, respectively. The majority of these coculture 
studies have used higher amounts of endothelial cells than bone cells, although the 
medium composition was often different. Moreover, among these works only one 
mentions a preliminary cell ratio study to justify the selected ratio used 41. Although 
authors did not show any results, they stated that a ratio of EC:osteoblasts between 
5:1 an 10:1 resulted in the presence of both cell types after 1 week of culture, whereas 
ratios of 1:1, 1:5 and 1:10 resulted in substantial reduction of EC number after the 
same period. In the present work, a relative cell ratio study was also performed, with an 
increasing on the relative amount of HUVECs: 25%HUVEC-75%MSC, 50%HUVEC-
50%MSC and 75%HUVEC-25%MSC, to investigate how the different ratios could 
influence cell behavior. Regarding metabolic activity (Fig. 5A), monoculture reaches 
the maximum at day 7, which is probably related to a higher MSC proliferation. In the 
coculture, in the following 2 weeks there was a significant increase in metabolic activity, 
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mostly related to a higher CoMSC proliferation, as observed earlier. This one-week 
difference may be related to the decrease in cell number of ECs in the coculture that 
was further compensated with CoMSC proliferation (Fig. 5B). The cell quantification 
assay provided additional information on the behavior of the two cell types at each cell 
ratio throughout the time (Fig. 5B). As expected, higher initial amounts of HUVECs led 
to a higher percentage of HUVECs in the coculture at day 21. Additionally, HUVECs 
relative number decreased throughout time, while MSCs increased using all the three 
relative cell ratios tested. In short time studies the initial cell seeding may not be 
essential, although for longer periods the cell ratio in the coculture needs to be 
carefully evaluated. Concerning ALP activity (Fig. 6A) no major differences were found 
between the different cell ratios until the last week, where the ratio with higher relative 
amounts of MSC presented higher ALP activity.  
Additionally, cell studies were also performed in the presence of osteogenic 
media. This allowed assessing the in vitro mineralization of MSC in contact with ECs 
due to the presence of an inorganic phosphate source (beta-glycerophosphate). It was 
possible to observe mineral deposits in the cell culture of all the ratios (Fig. 7). 
Moreover, cells in osteogenic conditions showed some changes in cell morphology 
comparing to cells in basal conditions (Fig. 7). However, regarding ALP activity, no 
major differences were found between basal and osteogenic conditions in all ratios 
(Fig. 6).  
Collectively, the present findings demonstrate that, by coculturing MSCs with HUVECs, 
there was not only an enhancement of osteogenic differentiation, but also a significant 
increase on MSCs proliferation. This augmentation in cell proliferation occurred in the 
presence of ECs, independently of relative cell ratios, but was favored by higher 
relative amounts of HUVECs. The main conclusions drawn from this work may be 
helpful for the development of a strategy for large-scale production of mesenchymal 
stem cells committed into the osteogenic lineage for tissue engineering applications, 
where a high amount of cells is required. Further studies are being carried out to 
assess the relevance of the present findings in an in vivo scenario. Previous results 
from our group provided a clear indication that ECs are also able to induce the 
commitment of MSCs into the osteogenic lineage in vivo. In fact, when both cell types 
were cocultured within a 3D matrix and then implanted in a rat femoral critical-sized 
defect, there was a significant increase in mineralization compared with the 
implantation of MSC alone 30. Additional studies are being carried out to get further 
insight into cocultured cell behavior in vivo, under different experimental conditions. In 
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case of success, that knowledge would be useful for developing minimally invasive 
regenerative therapies using injectable 3D matrices as (multi)cell delivery systems 29-32. 
This work constitutes a step forward in the pursuit for a better understanding of 
the interaction between these two cell lines, which can easily find application in several 
other tissue engineering approaches where vascularization is of prime importance. To 
our knowledge, the current paper showed for the first time that coculturing MSC with 
HUVECs significantly increased MSCs proliferation, independently of the relative cell 
ratio. 
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ABSTRACT  
 
In this work, human mesenchymal stem cells (hMSC) immobilized in RGD-
coupled alginate microspheres, with a binary composition of high and low molecular 
weight alginate, were investigated. Cells immobilized within RGD-alginate 
microspheres (during 21 days) showed metabolic activity with an overall viability higher 
than 90%, short cell extensions and, when induced, they were able to differentiate into 
the osteogenic lineage. In osteogenic conditions (comparing to basal conditions) 
immobilized cells presented alkaline phosphatase (ALP) activity and an upregulation of 
ALP, collagen type I and Runx 2 expression. Moreover, mineralization was also 
detected in immobilized cells under osteogenic stimulus. In addition, it was 
demonstrated for the first time that MSCs immobilized in this 3D matrix were able to 
enhance the ability of neighboring endothelial cells to form tube-like structures. Overall, 
these findings represent a step forward in the development of injectable stem cell 
carriers for bone tissue engineering. 
 
 
Keywords: Biomaterials, Angiogenesis, Bone Tissue Engineering, Regeneration, Cell 
Encapsulation, Mesenchymal Stem Cells, RGD peptide. 
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INTRODUCTION 
 
The development of injectable hydrogels for bone tissue engineering, allowing 
the localized and controlled delivery of cells with a high viability, offers an attractive 
strategy to fill-in bone defects. These polymeric systems can be implanted in the body 
using non-invasive surgical procedures, which reduce patient discomfort and promote 
faster recoveries at lower costs 1. For this type of strategy, calcium-crosslinked sodium 
alginate hydrogels have several advantageous features over other gel matrices used 
for cell immobilization, namely the ability to: a) crosslink in situ under mild conditions; b) 
encapsulate living cells; c) form 3D constructs; and d) be easily sterilized and stored 2, 
3. As a consequence, alginate, a natural polysaccharide extracted from seaweed, has 
been extensively used in the form of microspheres for cell immobilization 4-6. 
Additionally, microspheres can be prepared in a controlled way, resulting in beads with 
a narrow size distribution. These regular spherical particles with a controlled size, 
combined with a vehicle with in situ gel-forming ability, can be used as an injectable 
bone filler system 7. 
Alginate, an originally non-cell interactive polymer, can additionally be covalently 
modified with peptides containing the RGD sequence to promote cell adhesion 8, 9. 
Moreover, its molecular weight can be modified through irradiation and oxidation to 
modulate its viscoelastic properties, as well as its degradation rate [9]. The lower 
viscosity of the irradiated polymer results in reduced shear forces during the cell-
polymer mixing process and, consequently, in higher cell viability 10. Previous studies 
using RGD-alginate microspheres with a binary composition of high and low molecular 
weight already demonstrated the usefulness of this 3D system for the immobilization of 
MC3T3-E1 osteoblast-like cells 8, 11. 
In the context of bone regeneration, it seems relevant to investigate the use of 
alginate microspheres as carriers for more clinically relevant cell types, such as human 
mesenchymal stem cells (hMSCs). hMSCs have been widely investigated for bone 
tissue engineering strategies due to their high proliferative potential, their default 
osteogenic differentiation pathway, and their paramount role in endochondral and 
intramembranous bone formation in vivo 12-15. The combination of these cells with 
alginate hydrogels has already shown some encouraging results. Markusen et al. 
demonstrated that MSCs could be encapsulated in RGD-alginate beads maintaining a 
viability higher than 80% during two weeks 16. Duggal et al. provided some insights on 
cell behavior changes when moving from a 2D to a 3D system, using alginate as the 
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culture substrate 17. However, none of these studies examined the ability of MSCs 
immobilized in this 3D matrix to influence the formation of tube-like structures by 
endothelial cells. 
Angiogenesis is the process by which the budding of pre-existing vessels 
extends the vascular network, which involves, in an initial phase, recruitment of 
endothelial cells and, later on, pericytes and smooth muscle cells to the development 
of capillaries and large vessels, respectively 18, 19. Angiogenesis is closely associated 
with bone resorption and remodeling, which makes it a key process in the success of 
bone regeneration strategies 20, 21. 
Besides being a natural source for bone cells, MSCs may also play a 
fundamental role in the angiogenesis process 22. These cells are capable of influencing 
endothelial cells, by promoting their migration and tube-like structures formation, as 
demonstrated by Gruber et al. 23. Potapova and co-workers additionally showed that 
conditioned medium from hMSCs culture supported migration, extracellular matrix 
invasion and survival of endothelial cells 24.  
In the present work, the viability, metabolic activity and osteogenic potential of 
hMSCs immobilized within RGD-alginate microspheres and cultured under basal and 
osteogenic induction conditions were characterized in detail. The ability of this cell-
material 3D construct to enhance the sprouting of vessels, under influence of 
neighboring endothelial cells, was also investigated. The development of an injectable 
system, able to simultaneously provide a source of viable bone cells and to stimulate 
an angiogenesis-like response in the host, may represent a step forward in bone 
regeneration strategies. 
 
 
MATERIALS AND METHODS 
 
Alginate preparation 
Alginate for cell immobilization was prepared as a binary composition of high and 
low molecular weight alginate, as previously described by Evangelista et al. [8]. 
Sodium alginate powder with a high content of guluronic units (MVG Protonal LF 20/40, 
a gift from FMC Biopolymers, Oslo, Norway) was used as the high molecular weight 
component (HMW). The low molecular weight (LMW) alginate was obtained by gamma 
irradiating HMW with a cobalt-60 source, as previously described by Kong et al. 10.  
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The alginate preparation consisted in a three-steps procedure, as described by 
Evangelista et al. 8. Firstly, alginates with both molecular weights were purified through 
dialysis against distilled and deionized (DD) water for 3 days, followed by oxidation with 
sodium periodate. Then, covalent grafting of the oligopeptidic sequence of (Glycine)4-
Arginine-Glycine-Aspartic acid-Serine-Proline (abbreviated as G4-RGDSP; Peptide 
International, USA) was carried out using aqueous carbodiimide chemistry 9. For this 
latter step, 22 µmol of the peptide were used per gram of alginate polymer. Alginate gel 
for cell immobilization was prepared in 0.9 % sodium chloride (NaCl, Sigma) at a final 
concentration of 2 wt-%. It was composed of a 50:50 mixture of oxidized and RGD-
modified alginate (25 wt-% HMW, 75 wt-% LMW) and unmodified HMW purified 
alginate. 
 
Cell cultures 
Human mesenchymal stem cells (hMSC, Lonza) were cultured at 37ºC under a 
5% CO2 humidified atmosphere and expanded in MSCGM (MSC growth medium, 
Lonza). For the experiments, cells were used at passage 8 and cultured in basal 
medium: Dulbecco’s modified Eagle medium with low glucose (DMEM, Gibco), 
supplemented with 10% v/v inactivated fetal bovine serum (FBS, Gibco) and 1% v/v 
penicillin/streptomycin (P/S, Gibco). To induce hMSCs differentiation along the 
osteoblastic lineage, cells were cultured with osteogenic medium: basal medium 
supplemented with 10 mM β-glycerophosphate (Sigma), 10-8 M dexamethasone 
(Sigma) and 50 µg/mL ascorbic acid (Fluka). The culture medium was changed every 
other day. 
Human umbilical vein endothelial cells (HUVECs, ScienCell) were cultured at 
37ºC under a 5% CO2 humidified atmosphere, in M199 medium (Sigma) supplemented 
with 10% v/v inactivated FBS, 1% v/v P/S, 0.1 mg/mL of heparin and 0.03 mg/mL of 
endothelial cell growth supplement (Sigma) in 0.1% w/v collagen coated flasks. 
 
Immobilization and dynamic culture of hMSCs within alginate microspheres 
For immobilization within alginate microspheres cells were harvested before 
reaching confluence, using 0.05% w/v trypsin/ethylenediamine tetraacetic acid (EDTA) 
solution, then resuspended in 0.9 wt-% NaCl and loaded in a 5 mL syringe. After 
centrifugation and discarding of the supernatant, cells were homogeneously mixed with 
2 wt-% RGD-modified alginate solution, using a dual-syringe system, with a final 
concentration of 20x106 cell/mL of alginate solution. Subsequently, the alginate-cell 
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suspension was extruded under a coaxial nitrogen flow using a Var J1 encapsulation 
unit (Nisco, Switzerland) at a speed of 40 mL/h (Single-syringe infusion pump, Cole 
Parmer), to an isotonic 0.1 M CaCl2 solution to crosslink the alginate molecules. The 
microspheres were kept therein for 10 min, then rinsed in Tris-buffered saline (TBS) 
and finally rinsed in culture medium. All microspheres produced were uniformly 
spherical with an average diameter of 820 ± 30 µm (Fig. 1).  
 
 
Figure 1. Photomicrograph of RGD-grafted alginate microspheres, illustrating their spherical 
and uniform shape. The average diameter of microspheres measured was 820 ± 30 µm (n = 
100) (Bar = 500 µm). 
 
 
Cells immobilized within RGD-alginate microspheres were cultured under 
dynamic culture conditions for up to 21 days, using 100 mL spinner flasks (Bellco 
Biotechnologies, Vineland, NJ, USA). Half of the microspheres were cultured in basal 
medium and the other half in osteogenic medium. The microspheres were maintained 
at 37ºC under a 5% v/v CO2 humidified atmosphere. For control purposes, monolayer 
(2D) studies were carried out using hMSC suspensions seeded directly in 24 well 
plates with a final concentration of 3x103 cells/cm2. 
 
Cell quantification, viability and metabolic activity 
At days 1, 7, 14 and 21, for each condition, three samples containing 
microspheres were transferred from the spinner flask to a 24 well plate. Then, the 
number of microspheres per well was counted. Finally, cells were released from the 
microspheres through alginate dissolution using a 50 mM EDTA solution in PBS (pH 
7.4) for 5 min. Cells were quantified and their viability was determined using the trypan 
blue exclusion test. For that purpose, an aliquot of cell suspension was mixed with 0.4 
wt-% trypan blue (Sigma) and then transferred to a Neubauer chamber for counting. 
Cell viability was determined by scoring the percentage of unstained cells in the total 
cell number.  
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To assess metabolic activity three samples of microspheres for each condition 
were removed from the spinner flasks at days 1, 7, 14 and 21 and transferred to a 24 
well plate. A resazurin solution (Sigma) was added to fresh medium at a final 
concentration of 10% (v/v). Cells were incubated in this solution at 37ºC for 4 h, after 
which 100 µL/well were transferred to a 96 well black plate and fluorescence was 
measured (530 nmEx/590 nmEm) in a Spectra Max Gemini XS (Molecular Devices). The 
fluorescence was normalized to the number of microspheres per well. 
 
Microscopic analyses of immobilized cells 
After fixation in 4% paraformaldehyde/TBS for 20 min and further 
permeabilization with 0.1 % TritonX-100 (Sigma) for 5 min, the cell cytoskeleton was 
stained for F-actin with Alexa Fluor 488-phalloidin (Molecular Probes) and the cell 
nuclei with propidium iodide (Sigma). The morphology of immobilized cells was 
analyzed using confocal laser scanning microscopy (CLSM) (Leica SP2AOBS; Leica 
Microsystems).  
For scanning electron microscopy (SEM) observation, microspheres were 
washed twice in TBS and fixed in 1.5% glutaraldehyde in sodium cacodylate (0.14 M) 
for 1 h at room temperature, followed by dehydration with a graded ethanol series 
(60%, 70%, 80%, 90% and 99%) for 10 min in each solution. Microspheres were 
maintained in 99% ethanol until critically point dried (CPD 7501, Quorum 
Technologies). After sectioning the microspheres with a blade, they were sputter-
coated with gold using a JEOL JFC-100 Fine Coat Ion Sputter device and observed 
using a JEOL JSM-6301F scanning electron microscope (SEM). 
 
Quantification of alkaline phosphatase (ALP) activity 
For quantitative ALP analyses, three samples of cell lysates for each condition, 
obtained by brief sonication in ice with 1% v/v Triton X-100, were incubated with the 
chromogenic substrate 2 mM ρ–nitrophenol phosphate in 0.2 M bicarbonate buffer (pH 
10), 0.05% v/v Triton X-100, and 4 mM MgCl2 (Sigma) for 1 h at 37ºC. The reaction 
was stopped by adding 1 M NaOH and absorbance was read at 405 nm in a microplate 
reader (SLT Spectra). The amount of product was obtained from a p-nitrophenol 
standard curve. The enzymatic activity was normalized to total protein concentration, 
obtained using the bicinchoninic acid protein assay (BCA, Pierce), and expressed as 
nmol/min/mg protein. 
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Assessment of mineralization by Von Kossa staining 
At day 21 microspheres were recovered from the spinner flasks and washed with 
TBS. After fixation in 4% paraformaldehyde/TBS for 10 min, samples were dehydrated 
in a gradient series of ethanol and then embedded in paraffin blocks. Later, sections of 
6 µm thickness were prepared. Prior to staining, sections were dewaxed in xylene and 
rehydrated in a decreasing gradient series of ethanol followed by water. Sections were 
then incubated in 2.5 wt-% silver nitrate (Sigma) for 30 min under UV light, followed by 
incubation in 5 wt-% sodium thiosulphate (Aldrich) for 3 min. Finally, sections were 
washed and imaged under an inverted microscope (Axiovert 200M, Zeiss). 
 
Phenotype analyses through mRNA expression 
At days 1, 7, 14 and 21, total RNA was extracted from three samples of cells 
entrapped in microspheres using the RNeasy Mini Kit (Qiagen) protocol, as 
recommend by the manufacturer. Subsequently, 0.25 µg of the total RNA were used 
for random hexamers first strand synthesis to generate single stranded cDNA using the 
SuperScriptTM First-strand synthesis system for RT-PCR (Invitrogen). RNA 
quantification was performed by using a NanoDrop 1000 spectrophotometer. 
After the cDNA synthesis reaction, qReal-Time PCR was carried out in a total 
volume of 20 µL of a mixture containing 1 µL of cDNA (corresponding to 12.5 ng of 
total RNA), 0.25 µM of each forward and reverse primers and 1x iQ SYBR Green 
Supermix (Bio-Rad). qRT-PCR experiments were run using an iQ5 (Bio-Rad) under the 
following conditions: 95°C for 3 min, followed by 40 cycles at 94°C for 30 s, 60°C for 45 
s and 72°C for 30 s, and the last step at 55º for 10 s. All reactions were performed in 
duplicate. After completion of the PCR cycling, melting curves, obtained by increasing 
the temperature from 60°C to 96°C in increments of 0.5°C, were examined to ascertain 
specificity of the PCR products. The housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as the endogenous assay control. Relative 
quantification of gene amplification by qRT-PCR was performed using the cycle 
threshold (Ct) values and relative expression levels were calculated as follows: 2^(Ct 
GAPDHgene - Ct gene of interest). The expression value for each target gene was 
normalized to the GAPDH value at each time point. Afterwards, the gene expression at 
each day was normalized to day 1, which was the same sample for basal and 
osteogenic conditions. The sequence and length of the primer pairs used is indicated in 
Table 1. 
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Table 1. Sequence of primer pairs used for qRT-PCR. 
Gene name Ref. sequence Sequence of primers (5’-3’) Length (bp) 
GAPDH NM_002046 AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 66 
ALP BC021289 AGAACCCCAAAGGCTTCTTC CTTGGCTTTTCCTTCATGGT 74 
COL1A1 NM_000088 GGGATTCCCTGGACCTAAAG  GGAACACCTCGCTCTCCA 63 
Runx2 NM_001024630 GTGCCTAGGCGCATTTCA GCTCTTCTTACTGAGAGTGGAAGG 78 
 
Induction of tube-like structures formation  
The effect of immobilized hMSCs on tube-like structures formation and 
development was investigated using HUVECs cultured in the commercially available 
3D matrix Matrigel (Becton Dickinson, USA). After 21 days of culture, microspheres 
containing the hMSCs, kept in basal and osteogenic conditions, were transferred to a 
48 well plate. The medium was removed and then 150 µL/well of matrigel basement 
membrane was added and allowed to stand for 30 min at 37ºC to form a gel layer. After 
gel polymerization, HUVECs (5x103 cells) were added to each well. The medium used 
in each condition consisted on an equal mixture of M199 (culture medium for HUVECs) 
and DMEM (expansion medium for MSCs). Matrigel without microspheres was used as 
control. 
A quantitative measurement of tube-like structure formation in Matrigel was 
carried out. Comparisons among HUVEC cultures plated simultaneously for the three 
different conditions were performed after 24 hours (three wells for each condition: 
matrigel alone, matrigel with microspheres kept in basal and osteogenic conditions). 
The number of tube-like structures formed (vessels) was then counted in each well. 
Each tubular structure observed between the ramifications was considered one vessel. 
Mean values were obtained by evaluating the three wells under the same treatment. 
The experiment was repeated three times. 
 
Detection of vascular endothelial growth factor (VEGF) 
After 21 days, samples of conditioned media from microsphere cultures 
maintained in basal and osteogenic conditions were collected from the spinner flasks 
and centrifuged to remove cell debris. Levels of VEGF released by the embedded 
hMSCs into the surrounding media were assessed using a commercial VEGF ELISA 
Kit (R&D Systems), as recommended by the manufacturer. 
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Statistical analyses 
Statistical analyses were performed using SigmaStat (Statistical Software, 
STAT32 MFC Application). Statistical significance was assessed by using two way 
analysis of variance (ANOVA) in conjugation with Tukey’s test, pairwase multiple 
comparison procedures. The comparison of results from the tube-like structures 
formation assays was conducted by one way ANOVA in conjugation with Tukey’s test. 
Differences were considerer statistically significant when p values were lower than 
0.05. All data are presented as mean values ± standard deviation. 
 
RESULTS 
 
Cell quantification, viability and metabolic activity 
hMSCs were recovered from the microspheres at days 1 and 21 and counted. 
Overall, the total number of cells per microsphere was not significantly different 
between the two conditions (basal and osteogenic) and between the two days 
evaluated (Fig. 2). 
 
 
Figure 2. Number of immobilized hMSCs per microsphere after 1 and 21 days in culture, in 
basal (BC) and osteogenic medium conditions (OC). Data are expressed as mean ± standard 
deviation (n=3). 
 
 
At days 1, 7, 14 and 21 post-immobilization, cell viability was assessed (Fig. 3). 
At day 1 it was approximately 90% in both conditions, and it did not markedly changed 
until day 21. Moreover, the fraction of viable cells was similar in the two media 
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conditions tested and was generally constant for 2 weeks (no significant differences 
were observed until day 14).  
These findings were confirmed by determining metabolic activity using the 
resazurin assay. As can be seen in Fig. 4, the metabolic activity of cells cultured under 
basal and osteogenic conditions was similar for each time point. Under both conditions, 
the cells metabolic activity slightly decreased during the first two weeks of culture, but 
recovered completely by the end of the culture period tested (21 days). 
 
 
Figure 3. Viability of hMSCs immobilized in RGD-grafted alginate microspheres in basal (BC) 
and osteogenic medium conditions (OC), after 1, 7, 14 and 21 days of culture. (* p ≤ 0.05; ** p ≤ 
0.01) Data are expressed as mean ± standard deviation (n=3). 
 
 
Figure 4. Metabolic activity of human mesenchymal stem cells immobilized within RGD-grafted 
alginate microspheres, using the resazurin based assay after 1, 7, 14, and 21 days of culture 
under basal (BC) and osteogenic medium conditions (OC). RFU: relative fluorescence units. (* 
p ≤ 0.05; ** p ≤ 0.01) Data are expressed as mean ± standard deviation (n=3). 
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Cell morphology 
hMSCs morphology inside alginate microspheres was assessed by CLSM by 
staining the F-actin filaments, as shown in Fig. 5. Cells interacted to some extent with 
the hydrogel matrix, as suggested by the presence of short cytoplasm extensions 
around the cells, but remained typically with a round shape. 
 
 
Figure 5. Cytoskeleton organization of human mesenchymal stem cells inside alginate 
microspheres stained with phalloidin Alexa Fluor 488 for F-actin (green) and propidium iodide 
(red) for nucleus  (Bar = 10 µm). 
 
 
SEM analyses allowed the observation of the inner part of microspheres, 
including the hydrogel structure embedding the cells. Fig. 6 shows SEM micrographs of 
the internal part of a microsphere with hMSCs, after 21 days in culture, confirming the 
presence of cells and their interaction with the hydrogel matrix. 
 
 
Figure 6. Scanning electron microscopy (SEM) images of hMSCs immobilized within alginate 
microspheres, cultured for 21 days. (A) Cells inside the microsphere; and (B) a 3.6 
magnification of the cell-alginate interface. 
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Cell differentiation 
 
Alkaline phosphatase activity 
As illustrated in Fig. 7, the alkaline phosphatase (ALP) activity of cells cultured 
under basal conditions remained relatively low and constant throughout the 
experiment, both in 2D (monolayer) and 3D (microsphere) cultures, indicating almost 
no hMSC differentiation under these conditions. There were no significant differences 
during the 21 days for each type of culture under basal conditions. However, when 
comparing 2D and 3D cultures, the latter ones showed significantly higher ALP activity 
values at days 1 and 21, while at day 14 2D cultures exhibited a significantly higher 
value.  
Monolayer cultures (2D) treated with osteogenic media exhibited a significant 
increase (p<0.001) of ALP activity from day 1 to day 7, when a plateau was reached. 
On the other hand, cells within microspheres (3D) exhibited ALP values that gradually 
increased over time. Comparing 2D with 3D cultures in osteogenic media, on the first 
day there were no significant differences. ALP activity levels were significantly higher in 
2D comparing to 3D cultures at day 7 (p<0.001) but no differences were observed at 
day 14. The ALP activity considerably increased in 3D cultures at day 21, becoming 
significantly higher than in 2D cultures (p<0.001). 
 
 
Figure 7. Expression of ALP activity by hMSCs cultured in monolayer (2D) and inside 
microspheres (3D), after 1, 7, 14, and 21 days, under basal (BC) and osteogenic medium 
conditions (OC). (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001) Data are expressed as mean ± standard 
deviation (n=3). 
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Von Kossa staining 
One of the hallmarks of osteogenic differentiation is the formation of extracellular 
mineralized deposits. To assess the presence of these deposits the von Kossa staining 
was performed. hMSCs immobilized in alginate microspheres under osteogenic 
conditions showed large areas of mineralization (dark), with mineral nodules after 21 
days of incubation, as illustrated in Fig. 8. Mineralization was not detected in 
immobilized cells cultured under basal conditions nor in microspheres without cells, in 
agreement with previous work 8. 
 
A B 
  
C D 
  
Figure 8. Optical microscopy observation of hMSCs immobilized and cultured for 21 days inside 
RGD-alginate microspheres, in basal conditions (A, B) and in osteogenic conditions (C, D). A 
and C microsphere outline with cells; B and D a microsphere detail at a higher magnification. 
Von Kossa staining was performed in 5 µm thick paraffin sections. 
 
 
Quantitative real time PCR analyses of osteogenic markers 
In order to study the gene expression profile of immobilized cells cultured in basal 
and osteogenic conditions, real time PCR analyses of osteoblastic differentiation 
markers were carried out at defined time points (1, 7, 14 and 21 days) (Fig. 9). One of 
the genes studied was the runt homology domain transcript factor Runx2, which is a 
key osteoblastic modulator during bone formation 25. Both in basal and osteogenic 
Chapter III 
 
 
 96 
conditions, Runx2 was significantly upregulated from day 1 to day 7 (p<0.001), 
reaching a maximum at the end of the first week of immobilization, in the case of 
osteogenic culture conditions (Fig. 9A). Runx2 expression levels were significantly 
higher in osteogenic conditions at day 7. Afterwards, a decrease was observed, 
although not significant. Finally, on day 21, the Runx2 expression significantly 
decreased comparing to day 7 (p<0.001). Overall, Runx2 expression was significantly 
higher in osteogenic conditions compared to basal conditions (p=0.001). 
ALP expression (Fig. 9B) was significantly higher (p<0.001) in cells cultured in 
osteogenic medium comparing to basal one, at all time points analyzed. In osteogenic 
conditions, a ten-fold increase was observed at the end of the first week and the ALP 
expression level remained unchanged on the second week. A small decrease occurred 
at the third week. The expression levels in basic medium conditions were kept low for 
all time points tested. 
Collagen type I, the major component of the extracellular matrix in bone tissue, 
was significantly upregulated (p<0.001) in osteogenic conditions during the first 2 
weeks of culture (Fig. 9C). In both media tested, this gene exhibited significantly higher 
mRNA levels (p<0.001) at day 14 comparing to days 7 and 21. 
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Figure 9. Human mesenchymal stem cells gene expression levels of three osteogenic markers: 
A) transcript factor Runx2; B) alkaline phosphatase; and C) collagen type I. These expression 
levels were obtained recurring to real-time PCR, after cell immobilization in RGD-grafted 
alginate microspheres at different time points (BC - basal conditions; OC - osteogenic 
conditions). (* p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001) Data are expressed as mean ± standard 
deviation (n=3). 
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Induction of tube-like structures formation by HUVECs: an in vitro model of 
angiogenesis 
Matrigel matrix serves as a substrate for in vitro endothelial cell invasion and 
tube-like structures formation assays, and can also be used to assess in vivo 
angiogenic activity. In this study, Matrigel was used to evaluate if immobilized hMSCs 
could influence the ability of endothelial cells (HUVECs) to form tube-like structures. In 
matrigel alone (control) HUVECs adhered to the surface within 18 h and formed 
networks of branching and anastomosing cells, with multicentric junctions that lasted 
24 to 48 h (Figs. 10 and 11), in agreement with previous reports 26, 27. In the presence 
of microspheres containing immobilized hMSCs, the amount of tube-like structures 
formed significantly increased, independently of the culture conditions used (Figs. 10 
and 11). Although microspheres cultured under osteogenic conditions promoted the 
highest amount of tube-like structures formation, it was not significantly different from 
the results obtained under basal conditions. 
VEGF was present in the conditioned medium collected from microspheres-
containing hMSCs maintained in basal and osteogenic conditions for 21 days, as 
assessed by ELISA analysis. This assay confirmed that the VEGF produced by the 
cells was able to diffuse into the medium. 
 
 
 
Figure 10. Quantification of tube-like structures formed by HUVECs cultured for 24 h alone on 
matrigel or in the presence of hMSCs immobilized inside RGD-alginate microspheres. Cultures 
were carried out in basal (BC) and in osteogenic medium conditions (OC). The control was 
matrigel alone. Measurements were taken from a representative experiment repeated three 
times. (** p ≤ 0.01; *** p ≤ 0.001) 
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A B 
  
Figure 11. Tube-like structures formed by HUVECs after 24 hours on matrigel. (A) HUVECs 
cultured alone on matrigel; and (B) HUVECs cultured in the presence of hMSCs immobilized 
inside RGD-alginate microspheres (Bar = 500 µm). 
 
 
DISCUSSION 
 
To construct a functional engineered tissue, relevant native cell types, or their 
precursors, have to be either included or recruited into the scaffold along with vascular 
cell types 19. Basically, this means that to accomplish this daunting task of mimicking 
functionality and complexity of natural tissues, encouraging infiltration of the host 
vessels is mandatory. This generally recognized demand has inspired the development 
of several distinct therapeutic angiogenesis approaches, based in the use of scaffolds 
combined with cells and/or growth factors 11, 28-30.  
As an organ, bone is not an exception in this need for vascular development. The 
clear synergy between bone formation and angiogenesis uplifted the development of 
strategies that incorporate neovascularization approaches 19, 31. In the present work, a 
system based on the combination of RGD-modified alginate, as a synthetic 
extracellular matrix, and hMSCs is proposed and analyzed in detail.  
The present work was designed to aim for the preparation of an injectable bone 
regeneration system. For that purpose, alginate microspheres with an average size of 
800 µm (Fig. 1) were prepared. This size range was selected mainly to facilitate 
handling during the several assays performed, although these 3D matrices can be 
easily reduced in size down to 200 µm by simply varying the type of the encapsulation 
unit used. Additionally, as previously pointed out, these microspheres can be combined 
with an hydrogel vehicle to assist injection, especially using the smaller sizes 7. The 
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reduction in size can further contribute to improve the exchanges between cells and 
medium, thus facilitating cells access to nutrients and oxygen. 
Markusen et al. previously encapsulated MSCs in alginate-GRGDY beads and 
investigated their viability and proliferation 16. Abbah et al. studied the osteogenic 
behavior of rabbit bone marrow cells encapsulated in alginate microbeads, with and 
without a poly-L-lysine coating, and reported an increase in cell number until day 14 32. 
More recently, Duggal et al. investigated the phenotype and gene expression of hMSC 
in a 3D alginate system as compared to a 2D culture 17. The present team already 
demonstrated that the present RGD-modified alginate hydrogel, in contrast with 
unmodified alginate, was able to promote a much higher level of adhesion and 
differentiation of MC3T3-E1 pre-osteoblastic cells 8. Also, Grellier et al. explored the 
ability of this matrix to enhance mineralization in a bone defect after immobilization of 
human osteoprogenitors combined with endothelial cells 11. Although in all these 
studies the authors showed the interest of using RGD-grafted alginate as a 3D matrix 
for bone tissue engineering applications, little information still exists about cytoskeleton 
organization, cell viability, cell-matrix interactions and cell differentiation. More 
importantly, the effect of the entrapped cells in the regulation of new vessel growth has 
never been assessed. The present work, besides successfully demonstrating that 
RGD-alginate microspheres promoted hMSCs adhesion, maintained their metabolic 
activity and supported their osteogenic differentiation, also showed the capacity of this 
3D cell culture system to enhance in vitro endothelial cell invasion and tube-like 
structures formation. 
Similarly to previous reports 16, 17, the present work demonstrated that hMSCs 
could be entrapped in RGD-alginate maintaining a high viability, and be kept 
metabolically active during 3 weeks under 3D culture. Moreover, hMSCs immobilized in 
this 3D scaffold were also able to respond to environmental biochemical cues from the 
media by differentiating when cultured in osteogenic media 32. 
Furthermore, the proliferation of immobilized cells in basal and osteogenic 
conditions was also assessed, during 21 days of dynamic culture conditions, by the 
resazurin-based assay and through cell quantification (Figs. 2 and 3). The results 
obtained using both assays showed no significant differences between basal and 
osteogenic conditions for every time point analyzed. Regarding metabolic activity there 
was a significant increase over the last week of culture. However, the total cell number 
did not significantly change from the beginning until the end of culture. This suggests 
that there was no proliferation inside the microspheres over the time course of the 
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experiment. Cell viability was also evaluated, revealing that the fraction of viable cells 
was similar in both environments and was kept higher than 90% until day 14 (Fig. 3). 
Although the total cell number was kept unchanged, the metabolic activity of 
immobilized cells increased (Fig. 4) which points to cell activities other than 
proliferation, such as cell differentiation by synthesis of extracellular matrix. The lack of 
proliferation could be due to minimal space for growth of entrapped cells, which are 
probably spatially constrained by the polymeric network. In another related 
independent work, Ma and co-workers 3 also observed proliferation inhibition of cells 
entrapped in alginate microspheres, which provide suspension conditions and arrest 
cells on G0G1 phase. 
In the current study, analyses of cytoskeleton organization demonstrated that 
cells were able to establish sites of interaction with the polymeric matrix (Figs. 5 and 6). 
As hypothesized by Evangelista et al. 8 the covalently coupled RGD peptides promote 
interaction with integrins of the cell membrane, thus leading to assembly of actin 
filaments. Cells immobilized in the matrix without RGD peptides remained round and 
were unable to establish interactions with the polymer 8. 
The ability of hMSCs to generate distinct lineages is now a well-established 
concept and their osteogenic differentiation potential has become one of the most 
widely investigated topics in bone regeneration 32. Promising results have been 
obtained when using osteoblasts differentiated from MSCs in bone regenerative 
processes 33, 34. In view of these facts, and aiming to develop a bone regeneration 
strategy, the differentiation of immobilized hMSCs towards the osteogenic lineage was 
explored by analyzing several cell differentiation markers. Firstly, the expression of 
ALP, an early osteoblastic marker, that reflects not only the stage of cell differentiation 
but also represents the percentage of committed osteoprogenitor cells, was evaluated. 
The activity of this enzyme increases during synthesis of the extracellular matrix, which 
corresponds to the beginning of cell differentiation 35. In this study, ALP activity was 
analyzed in immobilized cells and compared with cells growing in monolayer. In basal 
conditions, ALP values were higher in immobilized cells, with the exception of day 14. 
In osteogenic conditions, only at day 21 was ALP activity significantly higher in 
immobilized cells than in monolayer culture (Fig. 7). In osteogenic conditions, since 
cells were entrapped within the alginate matrix, contact with osteogenic factors may be 
slower, due to diffusion limitations, which could lead to a delay in osteogenic 
differentiation. That could explain for at least one-week retardation on the osteogenic 
process, when comparing to monolayer culture in the same conditions. As previously 
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pointed out, microspheres with a high diameter were used to facilitate handling, 
although their size can be considerably reduced using the present technology, down to 
200 mm. This size reduction would certainly contribute to facilitate exogenous 
stimulation by soluble factors. Nevertheless, after 3 weeks in osteogenic culture 
conditions, immobilized cells expressed ALP values two times higher than the 
monolayer culture. These findings seem to indicate that, despite the slower diffusion, 
the 3D structure was able to stimulate osteogenic differentiation. An additional 
evaluation of ALP expression from immobilized cells was carried out by real time RT-
PCR. Also, Von Kossa staining of immobilized cells cultured under osteogenic 
conditions showed formation of mineral deposits, which further confirms osteogenic 
differentiation (Fig. 8). Real time quantitative RT-PCR assays were performed for 
transcripts that code for osteoblast-related proteins, including a major transcription 
factor for regulating osteogenesis, Runx2 (Fig. 9A). Results showed that Runx2 
expression was affected during cell differentiation, with its level increasing during the 
osteogenic induction, which is in agreement with its function as a key transcription 
factor in the regulation of bone differentiation markers 25. In addition, since its activity 
may be modulated through cell contact with the extracellular matrix, the 3D alginate 
matrix could have had an important role in its regulation and have been responsible for 
its upregulation in basal conditions. In conformity with previous results, ALP expression 
was significantly upregulated under osteogenic conditions (Fig. 9B). Finally, the 
expression of collagen type I also increased during osteogenic differentiation, which is 
consistent with its role in osteoblast maturation (Fig. 9C) 36. In fact, ALP and type I 
collagen are crucial during extracellular matrix production, which is necessary for 
mineralization.  
As stressed before, a decisive factor that needs to be taken into account for bone 
regeneration strategies is angiogenesis, which is a process closely allied to 
osteogenesis. It plays a critical role in the initiation of fracture healing and in the 
promotion of endochondral and intramembranous ossification during bone growth 21, 37, 
38. During the angiogenesis process, by which the budding of pre-existing vessels 
extends the vascular network, endothelial cells are intensively recruited 18, 19. The 
Matrigel assay, a reconstituted basement membrane that promotes morphological 
differentiation of human endothelial cells, is a well-known system for studying 
angiogenesis induction 27. In the present work, the Matrigel assay demonstrated that 
hMSCs immobilized inside RGD-grafted alginate were capable of influencing 
angiogenesis by significantly enhancing the ability of neighboring endothelial cells to 
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form tube-like structures (Figs. 10 and 11). Since the two cell types were not in direct 
contact, these results suggest that growth factors produced by the hMSCs, like the 
vascular endothelial growth factor (VEGF) 39-41, may have influenced endothelial cells 
behavior. The presence of VEGF was detected in the culture medium, showing not 
only that hMSC were able to produce this signaling protein, but also that it was able to 
diffuse through the hydrogel network into the surrounding medium. 
Yu et al. recently provided further insights into the effect of alginate biopolymers 
as synthetic extracellular matrix and RGD peptides as endothelial cell-matrix mediators 
42. In their study they showed that that RGD peptides conjugated to alginate promoted 
an enhancement of angiogenesis when studying the regeneration of cardiac tissue by 
improving myocardial function.  
Overall, in the present study, it was demonstrated that RGD-grafted alginate 
microspheres not only promoted hMSCs adhesion and supported their osteogenic 
differentiation, but also provided the adequate environment for these cells to stimulate 
neighboring endothelial cells to form tube-like structures. 
 
 
CONCLUSIONS 
 
This study showed that RGD-alginate hydrogels were able to support hMSCs 
differentiation along the osteogenic lineage when cells were immobilized within this 3D 
matrix. Moreover, it was demonstrated that this system enhanced the ability of 
neighboring endothelial cells to form tube-like structures. Collectively, these findings 
demonstrate the potential of this approach as a therapeutic strategy for bone 
regeneration. 
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ABSTRACT  
 
Cell-based therapies offer an attractive approach for revascularization and 
regeneration of tissues. However, and despite the pressing clinical needs for effective 
revascularization strategies, the successful immobilization of viable vascular cells 
within 3D matrices has been difficult to achieve. In this paper the in vitro potential of a 
natural, injectable RGD-alginate hydrogel as an in situ forming matrix to deliver 
endothelial cells was evaluated. Several techniques were employed to investigate how 
these microenvironments could influence the behavior of vascular cells, namely their 
ability to promote the outward migration of viable, proliferative cells, retaining the ability 
to form a 3D arrangement. Cells within RGD-grafted alginate hydrogel were able to 
proliferate and maintained 80% of viability for at least 48h post-immobilization. 
Additionally, entrapped cells created a 3D organization into cellular networks and, 
when put in contact with matrigel, cells migrated out of the RGD-matrix. Overall, the 
obtained results support the idea that the RGD peptides conjugated to alginate provide 
a 3D environment for endothelial cells adhesion, survival, migration and organization. 
 
 
Keywords: Alginate; Cell adhesion; Endothelial cell; RGD peptide; Scaffold. 
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INTRODUCTION 
 
The field of regenerative medicine is based on the patient’s own competence to 
induce the repair of injured tissues, and consequently restore their natural functions in 
situ. This natural healing capacity, coupled with the use of an adequate scaffold 
providing a synthetic extracellular matrix (ECM) to organize cells into a three-
dimensional (3D) architecture, guides the formation and growth of the new tissue.  
Paramount to a good performance of a biomaterial scaffold is its capacity to allow 
the proper vascularization and therefore, vascular cell survival and organization. 
Attempts to mimic vascularization in engineered tissues will lead to more clinically 
relevant cell-based therapies. Aside from strategies based on promoting angiogenesis 
from the host, in the past few years a growing interest in biomaterial in vitro 
prevascularization has emerged into the limelight 1-4. Although vascularization remains 
an unsolved challenge in tissue engineering, encouraging developments have been 
made to grow and maintain, in vitro, these self-assembled biological vascular networks 
5, 6. Polymers with the ability of forming 3D hydrogel networks offer an exciting 
possibility for the in situ delivery of vascular cells, allowing their organization into a 3D 
architecture and assisting cells in repopulating the surrounding tissue after 
transplantation 7. 
Hydrogels have been proposed with different functions in the field of tissue 
engineering, namely as space filling agents, drug and cell delivery vehicles and 3D 
scaffolds 7. Hydrogel matrices are water-swollen crosslinked polymeric structures that 
are mechanically flexible and simulate to a certain extent the natural ECM 8. Highly 
hydrated hydrogels are advantageous for tissue regeneration applications because of 
their high permeability to oxygen, nutrients and water-soluble metabolites 9. 
Additionally, some hydrogel matrices can be prepared from soluble precursors 
solutions that crosslink in situ, which allows their application at the injury site by 
minimal invasive methods 8. One example is alginate, a hydrogel-forming natural 
polysaccharide that has been intensively investigated for a variety of biomedical 
applications, namely for cell delivery in tissue regeneration therapies 10. Although being 
originally a non cell-interactive polymer, alginate can be covalently modified with 
peptides containing the amino acid sequence arginine-glycine-aspartic acid (Arg-Gly-
Asp, RGD) to promote cell adhesion 11, 12. Moreover, its molecular weight can be 
modified through irradiation and oxidation to modulate its viscoelastic properties, as 
well as its degradation rate 12. The lower viscosity of the irradiated polymer results in 
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reduced shear forces during the cell-polymer mixing process and, consequently, in 
higher cell viability 13. Previous studies from our group, using RGD-alginate 
microspheres with a binary composition of high and low molecular weight, already 
demonstrated the usefulness of this 3D system for the immobilization of osteoblast-like 
cells 11, 14, 15. Alginate, coupled with vascular endothelial growth factor (VEGF), has also 
been proposed as macroporous scaffolds for endothelial progenitor cells (EPCs) 
delivery 16. However, only a limited number of reports exist so far regarding the use of 
injectable in situ crosslinking systems for vascular cell delivery 15, 17-20. For example, 
Kraehenbuehl and co-authors incorporated a Tß4 peptide in a synthetic hydrogel, to 
stimulate vascular organization 21. In a previous work with alginate, immobilized 
endothelial cells showed a fast decreased in metabolic activity throughout time, due to 
the high alginate concentration that impeded cell-cell contact 15. 
The aim of this study was to evaluate the applicability of injectable RGD-alginate 
hydrogels as vehicles for the minimally invasive delivery of endothelial cells. Several 
techniques were employed to investigate the outcome of these microenvironments on 
vascular cell behavior, namely on their ability to promote the outward migration of 
viable, proliferative cells, retaining the ability to form tubular-like structures. 
 
 
MATERIALS AND METHODS 
 
Alginate preparation 
Alginate for cell immobilization was prepared as a binary composition of high and 
low molecular weight alginate, as previously described 11, 14. Sodium alginate powder 
with a high content of guluronic units (M VG Protonal LF 20/40, a gift from FMC 
Biopolymers, Oslo, Norway) was used as the high molecular weight component 
(HMW). The low molecular weight (LMW) alginate was obtained by gamma irradiating 
HMW with a cobalt-60 source, as previously described by Kong et al. 13.  
The alginate preparation consisted in a three-steps procedure, as explained by 
Evangelista et al. 11. Firstly, alginates with both molecular weights were purified through 
dialysis against distilled and deionized water for 3 days, followed by oxidation with 
sodium periodate. Then, covalent grafting of the oligopeptidic sequence of (Glycine)4-
Arginine-Glycine-Aspartic acid-Serine-Proline (abbreviated as G4-RGDSP; Peptide 
International, USA) was carried out using aqueous carbodiimide chemistry 12. For this 
latter step, 22 µmol of peptide were used per gram of alginate polymer. Alginate gel for 
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cell immobilization was prepared in 0.9 wt-% sodium chloride (NaCl, Sigma) at a final 
concentration of 1 wt-%. It was composed of a 50:50 mixture of HMW and LMW, both 
alginates oxidized and RGD-modified. For control purposes the same mixture of HMW 
and LMW was used but without RGD. 
 
Formation of alginate hydrogel  
Hydrogel formation was carried out under simulated physiological conditions 
using an internal gelation strategy as previously described 22, 23. Briefly, alginate gel 
precursor solutions at 1 wt% in 0.9 wt% NaCl were mixed with an aqueous suspension 
of calcium carbonate (CaCO3, Fluka) until homogenization. The gelling process was 
triggered by adding a fresh solution of glucone delta-lactone (GDL, Sigma). The molar 
ratio of CaCO3/GDL was set at 0.125. Gel formation continued at standard incubator 
conditions (37ºC, 5% CO2) for approximately 1h. The gelation time can be easily 
adjusted by changing the molar ratio of CaCO3/GDL, as previously shown 24. 
 
Human umbilical vein endothelial cell culture 
Human umbilical vein endothelial cells (HUVECs, ScienCell) were routinely 
grown at 37ºC under a 5% CO2 humidified atmosphere, in M199 medium (Sigma) 
supplemented with 10% v/v inactivated FBS, 1% v/v Penicillin/Streptomicin, 0.1 mg/mL 
of heparin and 0.03 mg/mL of endothelial cell growth supplement (Sigma) in 0.1% w/v 
collagen coated flasks. For the experiments cells were used until passage 8 and 
cultured in complete endothelial cell growth medium-2 (EGM-2, Lonza).  
 
Cell attachment on alginate films 
Solutions of unmodified and RGD-grafted alginate at 1 wt-% were spin-coated 
(Spin Coater, SCS G3P-8) on plastic coverslips (Starstedt) previously coated with poly-
lysine (Sigma). Immediately after alginate deposition (100 µL, 9000 rpm, 1 min), 
crosslinking was initiated by immersion in 0.1 M CaCl2 solution. Then, films were 
transferred to a 24 well plate and carefully rinsed with sterile water and culture medium. 
A total of 40,000 cells were seeded on the top of the alginate films and cultured at 37ºC 
under 5% CO2 humidified atmosphere. After 24h, films were imaged under an inverted 
microscope (Axiovert 200M, Zeiss). 
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3D cell culture within alginate hydrogel 
For immobilization within alginate hydrogel, cells were harvested before reaching 
confluence, using 0.05% w/v trypsin/ethylenediamine tetraacetic acid (EDTA) solution 
(Sigma). After centrifugation and discarding of the supernatant, HUVECs were 
homogeneously mixed at a final concentration of 20x106 cell/mL with 1 wt-% of alginate 
gel precursor and crosslinking agents as described on section 2.2. Crosslinking was 
promoted directly in the culture plates by placing 20 µL of the solution into each well of 
a 24 well suspension culture plate, which allowed obtaining small and uniform hydrogel 
matrices. Samples were placed in the incubator at 37ºC under 5% CO2 humidified 
atmosphere during 1h, until gelling was completed. Finally, complete EGM-2 was 
added do each well. The cell-loaded alginate hydrogels were cultured during 72h and 
medium was changed after 24h. As a control, cells were entrapped within alginate 
without RGD and kept under the same conditions. For the different cell studies three 
hydrogel matrices were analyzed for each condition. 
 
Cell viability  
At different time points (0, 24 and 48h) three hydrogel matrices for each condition 
were dissolved using a 50 mM EDTA solution in PBS (pH 7.4) for 5 min to allow cell 
recovery. Cell viability was determined using the trypan blue dye exclusion test. For 
that purpose, an aliquot of cell suspension was mixed with 0.4 wt-% trypan blue 
(Sigma) and then transferred to a Neubauer chamber for counting. Cell viability was 
determined by scoring the percentage of unstained cells in the total cell number.  
 
CFSE-based cell-division tracking 
HUVECs were incubated with carboxyfluorescein succinimidyl ester (CFSE, 
Molecular Probes) for 15 min at 37°C at 10 µM CFSE in PBS, washed twice with PBS 
with 20% FBS and once in medium. CFSE-labeled cells were entrapped in alginate 
with and without RGD peptides as previously described. To monitor cell proliferation 
rates, cells were recovered by dissolving the alginate matrices with EDTA and the 
levels of CFSE in cells were analyzed in triplicate on a FACSCalibur flow cytometer 
(Becton Dickenson). Data processing was performed using FlowJo software 8.7.flow 
cytometry. As cells divide, the CFSE fluorescence intensity is split roughly evenly 
between the two daughter cells. This intensity provides an indirect measurement of the 
number of divisions a cell has undergone. 
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Cell morphology 
After 24 and 48h, HUVECs morphology was evaluated through staining of their 
cytoskeleton. For that purpose, cells were fixed in 4% w/v paraformaldehyde/tris 
buffered saline (TBS) for 20 min, permeabilized with 0.1% v/v TritonX-100 (Sigma) for 
5 min, and finally the cell cytoskeleton was stained for F-actin with Alexa Fluor 488-
phalloidin (Molecular Probes) and the cell nuclei with Hoechst 33342 at 1 µg/mL. The 
morphology of entrapped cells was analyzed using confocal laser scanning microscopy 
(CLSM; Leica SP2AOBS, Leica Microsystems).  
 
Immunoflurescent analysis of von Willebrand expression 
After 24h, HUVECs immobilized within alginate hydrogels were fixed in 4% w/v 
paraformaldehyde/TBS for 20 min, and permeabilized with 0.2% v/v TritonX-100 
(Sigma) for 10 min. After washing, the primary antibody (1:200, vWF, DakoCytomation) 
was added and incubated overnight. Then, samples were washed and the secondary 
antibody (1:1000, anti-rabbit Alexa 594, Molecular Probes) was added and incubated 
for 1h at room temperature. Finally the nuclei were stained with Hoechst 33342 at 1 
µg/mL and samples were examined by CLSM. 
 
Phenotype analyses through mRNA expression of Angiopoetin-2 
Total RNA was extracted from HUVECs using the total RNA isolation kit 
(Macherey-Nagel), as recommended by the manufacturer. Subsequently, 1 µg of the 
total RNA was used as template for single strand cDNA synthesis with the Superscript 
pre-amplification system (Invitrogen) in a 20 µL final volume containing 20mM Tris-HCl 
(pH 8.4), 50mM KCl, 5 mM MgCl2, 10 mM DTT, 0.5 mM of each dATP, dCTP, dGTP 
and dTTP, 0.5 µg oligo(dT)12-18, and 50 U of reverse transcriptase. After incubation at 
42ºC for 50 min, the reaction was stopped at 70ºC for 15 min. After the cDNA synthesis 
reaction, qReal-Time PCR was carried out in a total volume of 25 µL of a mixture 
containing 1 µL of cDNA diluted at a 1:10 ratio (corresponding to 100 ng of total RNA), 
200 nM of each forward and reverse primers and 1x Mesa Green qPCR MaterMix Plus 
for Sybr Assay (Eurogentec). Primers of angiopoietin 2 (Ang-2) forward: 5´ 
GGATGGAGACAACGACAAATG 3´; reverse: 5’ GGACCACATGCATCAAACC 3´; 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward: 5’ 
AGCCACATCGCTCAGACAC 3´ and reverse 5´ GCCCAATACGACCAAATCC 3´. 
qRT-PCR experiments were run using an iQ5 (Bio-Rad) and analyzed with the iCycler 
IQTM software. Relative quantification of gene amplification by qRT-PCR was 
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performed using the cycle threshold (Ct) values and relative expression levels were 
calculated using the 2^(-ΔΔCT) method. The expression value for each target gene was 
normalized to the GAPDH value at each time point. Afterwards, the fold change in the 
Ang-2 gene normalized to GAPDH and relative expression at time zero was calculated 
for day 2. For each PCR, samples were analyzed in duplicate and three independent 
experiments were performed. 
 
In vitro cell migration assay 
The cell migration assay was carried out using FluoroBlokTM inserts with an 8 µm 
pore size (Becton Dickenson) in a 24-well tissue culture insert carrier plate (Becton 
Dickenson). Cells were pre-labeled with the fluorescent probe CellTracker Green 
CMFDA (Molecular Probes) at 15 µM for 30 min, and then entrapped within RGD-
modified and unmodified alginate matrices, as previously described. Afterwards, the 
hydrogel matrices were transferred to the apical side of the FluoroBlok inserts, and 
EGM-2 medium with (lower chamber) or without (upper chamber) growth factors was 
added. Fresh VEGF (Sigma) and fibroblast growth factor (FGF, Sigma) were added to 
the lower chamber every 24h to act as chemoattractants. At different time points (0, 
1.5, 5, 18, 24, 48 and 72h), fluorescence intensity from the basal side was measured in 
bottom-reading mode using a microplate spectrofluorimeter (BioTek), at wavelengths of 
492/517 nm (Ex/Em). To convert fluorescence readings into cell numbers, a standard 
curve was established for each experiment. Fluorescence images of migrating cells 
were collected using an inverted fluorescent microscope. Fluorescence-labeled cells 
within the alginate matrices were imaged by confocal microscopy. Samples were 
assayed in triplicate and the experiment was repeated three times. 
 
In vitro Matrigel sprouting assay 
The ability of outward migrating cells to form tubular-like structures was analyzed 
by placing the cell-loaded alginate hydrogel matrices in contact with a matrigel 
basement membrane layer (Becton Dickinson). Samples were cultured with complete 
EGM-2 and placed in the incubator at 37ºC under 5% CO2 humidified atmosphere. 
After 24h, cell sprouts were visualized at different magnifications under an inverted 
microscope (Axiovert 200M, Zeiss). 
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Activity of matrix metalloproteinases (MMPs) by zymography 
To detect MMP enzymatic activity from entrapped HUVECs, cell culture 
supernatants were analyzed by gelatin-zymography. After 24 and 48h supernatants 
were collected and centrifuged to remove cell debris. Conditioned media were loaded 
into gelatin-SDS polyacrylamide gels. Sample volumes were adjusted to yield 
equivalent total cell protein contents, which were quantified by the Dc Protein assay kit 
(BioRad) in lysates of cells recovered from the hydrogels. The gel was run in 1x Tris-
Glycine SDS running buffer at 60 V (Mini Protean Tetra Cell system, BioRad). After 
electrophoresis, gels were washed twice and subsequently incubated in MMP 
substrate buffer for 16h at 37ºC. Afterwards, gels were washed and then stained with 
Coomassie Brilliant Blue R-250 (Sigma-Aldrich). MMPs proteolytic activity was 
visualized as the presence of clear bands against a blue background of Coomassie 
Blue-stained of gelatin substrate.  
 
Statistical analyses 
Statistical analyses were performed using SigmaStat (Statistical Software, 
STAT32 MFC Application). Statistical significance was assessed by using two-way 
analysis of variance (ANOVA) in conjunction with Tukey’s test, pairwase multiple 
comparison procedures. The comparison of results from the CFSE-based assay was 
conducted by one-way ANOVA in conjugation with Tukey’s test. The t-test was 
adopted for statistical comparison between the groups in the Ang-2 profile analysis. 
Differences were considered statistically significant when p values were lower than 
0.05. All data are presented as mean values ± standard deviation. 
 
 
RESULTS 
 
Cell behavior on RGD and unmodified alginate films 
Preliminary cell adhesion studies were performed in a 2D environment to better 
illustrate the biological interaction between HUVECs and the covalently modified 
alginate. HUVECs seeded onto RGD-coupled alginate hydrogels were able to attach, 
and were already well spread after 24h, while on control surfaces (unmodified alginate) 
cells were unable to adhere and formed cell clusters. This phenomenon was observed 
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under light microscopy and is well illustrated in Fig. 1. After medium change the cell 
aggregates formed on unmodified alginate were easily displaced and washed out. 
 
 
Figure 1. Photomicrographs of human umbilical vein endothelial cells (HUVECs) cultured on the top of 
alginate hydrogel films at 24h post-seeding without medium change: (A) RGD-modified alginate, (B) 
unmodified alginate (control). 
 
 
 
In situ crosslinking of alginate solutions 
Injectable in situ-crosslinkable hydrogels need to be able to adjust to complex 
forms at the site of injury. To confirm that alginate was able to conform to different 
shapes, gel precursor and crosslinking agents were mixed and hydrogels were casted 
in different molds as can be depicted in Fig. 2A. For the subsequent cell culture 
studies, hydrogels were prepared from 20 µL drops of alginate gel precursor solution 
mixed with cells (Figs. 2B, C and D). 
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Figure 2. A) Different shapes of alginate hydrogels obtained by an internal gelation method. The alginate 
was gelled in situ by the liberation of calcium ions from an insoluble compound (CaCO3) through pH 
decrease that accompanies glucone delta-lactone hydrolysis in solution. B) Formation of alginate matrices 
with immobilized cells obtained from a 20µL alginate drop by using a positive-displacement micropipette. 
C) and D) Representative images of alginate matrices used in this work. 
 
 
Effect of RGD peptides on HUVECs survival: Viability and angiopoietin-2 
expression 
Cell viability, morphology and proliferation studies were performed to analyze 
cellular behavior under 3D conditions, within adhesive and non-adhesive alginate 
hydrogels. HUVECs recovered from both types of hydrogel matrices immediately after 
entrapment (day 0) did not present significant differences in terms of viability (Fig. 3A). 
After 24h, cells within RGD-alginate matrices already presented a higher viability (80%) 
compared to cells within unmodified hydrogels (63%). After 48h, this difference 
became more pronounced, with cellular viability decreasing to nearly 40% within 
unmodified alginate, and remaining at near 80% within RGD-alginate. 
Angiopoietin-2 (Ang-2) belongs to a family of angiogenic modulators that is 
almost exclusively produced by endothelial cells 25. To examine the Ang-2 expression 
in response to the presence or absence of RGD as cell-matrix mediator, a qPCR assay 
was carried out. As illustrated in Fig. 3B there were differences between the two 
conditions, with cells within unmodified alginate presenting a significantly higher Ang-2 
expression. 
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Figure 3. A) Viability of human umbilical vein endothelial cells (HUVECs) cultured under 3D conditions 
within RGD-modified (RGD-alg) and unmodified alginate (alg), estimated using the trypan blue exclusion 
assay. B) Gene expression levels of angiopoietin-2 (Ang-2) of HUVECs within RGD-modified and 
unmodified alginate by qPCR 48h pos-immobilization. Each experiment was performed three times, each 
in triplicate. Data are expressed as mean ± standard deviation (n=3). (* p ≤ 0.05) 
 
 
Cell morphology 
The morphology of immobilized HUVECs was assessed by CLSM by staining the 
F-actin filaments, as shown in Fig. 4. In RGD-alginate, after 24h, HUVECs were able to 
spread and build a cellular network, which was maintained at least for 48h post-
immobilization. Additionally, cells stained positively for the endothelial cell marker vWF. 
This network design was not attained within unmodified alginate, where cells remained 
with a round shape and presented no detectable cytoplasm extensions.  
 
 
Chapter IV 
 
 
 122 
 
Figure 4. Human umbilical vein endothelial cells (HUVECs) cultured under 3D conditions within alginate 
hydrogels with or without RGD peptides 48h pos-immobilization. A and B) Cells were staining with Alexa 
Fluor 488 phalloidin (in green) and Hoechst 33342 (nuclei in blue). C and D) Cells were analyzed for the 
endothelial marker von Willebrand factor (vWF) (red) and Hoechst 33342 (nuclei in blue). Constructs were 
visualized under confocal fluorescence microscope. A and C) Representative images of HUVECs 
immobilized within unmodified alginate (without RGD); B and D) HUVECs immobilized within RGD-
modified alginate. 
 
 
Proliferation of ECs-loaded hydrogels 
Cell proliferation on modified and unmodified alginate hydrogels was analyzed 
using the CFSE labeling assay. A representative histogram of flow cytometry data is 
shown in Fig. 5A. The extent of HUVECs proliferation is related with the decrease on 
CFSE staining intensity, demonstrating different rates of cell division for the two 
assayed conditions. Looking at the geometric mean of CFSE intensity represented in 
Fig. 5B it can be concluded that cells within RGD-alginate matrix presented a higher 
rate of cell division (lower CFSE intensity) than cells within the unmodified alginate. 
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Figure 5. A) CFSE histogram data obtained by flow cytometry for human umbilical vein endothelial cells 
proliferation within alginate hydrogels (curve 1 – cells without CFSE, curve 4 – cells with CFSE at day 0; 
line 2 – cells with CFSE after 48h within RGD-modified alginate (RGD-alg); line 3 – cells with CFSE after 
48h within unmodified alginate (alg). B) Geometric mean of CFSE intensity relative to cells with CFSE at 
day 0 (corresponds to maximum of intensity) of three different experiments. Data are expressed as mean ± 
standard deviation (n=3). (** p ≤ 0.01; *** p ≤ 0.001) 
 
 
Cell migration and MMPs activity 
Outward migration of HUVECs from alginate hydrogels was investigated using a 
transwell system. Fluorescence-labeled cells were entrapped within alginate matrices 
(Fig. 6A), and those that were able to escape from the hydrogel matrices were induced 
to migrate through the fluorescence-blocking membrane of the insert by chemotaxis 
(Fig. 6B). A time course of the cell migration up to 72h is illustrated by a representative 
experiment in Fig. 6C. Transwells with RGD-modified alginate matrices showed a 
significantly higher fluorescence throughout time, which corresponds to a higher 
number of cells that were able to cross the membrane of the fluoroblok. 
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Figure 6. (A) Human umbilical vein endothelial cells (HUVECs) labeled with CellTrackerTMgreen 
fluorescent marker immobilized within RGD-modified alginate matrix. (B) Fluorescently labeled migrating 
HUVECs at the basal side of the insert membrane. (C) Fluorescence intensity (relative to 0 hours) of 
fluorescently labeled HUVECs that evade the alginate matrix and migrate through the FluoroBlok 
membrane along a period of 72h. The experiment was performed three times, each in triplicate. Data are 
expressed as mean ± standard deviation (n=3). (*** p ≤ 0.001) 
 
 
The next step consisted in evaluating if the entrapped HUVECs that exited the 
alginate matrix retained the ability to form tube-like structures. In other words, the 
ability of RGD-alginate hydrogels to support outward migration of HUVECs from the 
matrix in an organized and functional way was assessed. Hydrogel matrices containing 
cells were embedded in matrigel (Fig. 7), to mimic implantation in tissues. After 24 and 
48h, no cellular sprouts were observed in the vicinity of control alginate matrices, but 
only a few dispersed cells. On the other hand, already after 24h, several cellular 
branches were protruding from the RGD-alginate hydrogel matrices, forming tubular-
like structures that invaded the surrounding matrigel layer. 
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Figure 7. Representative phase-contrast micrographs of human umbilical vein endothelial cells that have 
migrated out from the alginate matrix into the surrounding tissue mimic (Matrigel), after 24h, at different 
magnifications: A) a B) Unmodified alginate; C) and D) RGD-modified alginate. 
 
 
Endothelial cell migration through extracellular matrices is known to be 
dependent and controlled by MMP-mediated matrix degradation 26. High levels of 
protease expression are required for cells to survive and migrate. Zymography results 
(Fig. 8) show that HUVECs secreted the two active MMP2 species (62 and 64 kDa), 
which increased after 48h and were detected using unmodified and RGD-modified 
alginate. However, in the case of cells immobilized with alginate grafted with RGD 
peptides, a higher activity of both active MMP2 species was observed. Although the 
latent form of MMP9 (92kDa) was detected in the medium, its active species were not 
observed. 
 
 
Figure 8. Enzymatic activity of MMP-2 and MMP-9 obtained from human umbilical vein endothelial cells 
(HUVECs) supernatants analyzed by gelatin zymography. HUVECs entrapped within unmodified alginate 
for 24h (lane 2) and 48h (lane 3) and entrapped within RGD-modified alginate for 24h (lane 4) and 48h 
(lane 5). In lane 1 fresh medium was run as a control. These results are representative of three separate 
experiments. 
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DISCUSSION 
 
Three-dimensional (3D) scaffolds offer an exciting possibility to mimic 
functionality and complexity of native tissues. However, to construct a functional tissue, 
the formation of a vascular network is required. The vascularization of engineered 
tissues in vitro may be seen as an alternative to improve cell survival after 
transplantation, since functional blood vessels can facilitate transport of oxygen and 
nutrients. Moreover, considering the fact that several attempts to accomplish 
revascularization solely through delivery of growth factors have largely failed in clinical 
trials, endothelial cells transplantation stands out as a promising approach 27.  
Polymers with the ability to form 3D hydrogel networks, such as alginate, have 
been used in a variety of medical applications including cell encapsulation. In 
particular, this anionic polysaccharide has, as additional advantage, the capacity to be 
transformed from liquid to solid in situ under mild conditions. The idea behind this work 
was to analyze this injectable biomaterial as a vehicle for vascular cell-based 
therapies, providing a microenvironment that enhances cell survival and that could be 
used for repopulation of surrounding tissue after injection. From an application 
standpoint, these injectable matrices would also help to tackle problems of surgical 
invasiveness. 
Alginates are non-fouling and non-adhesive to cells, which can be overcome 
through chemical modification with cell-adhesion peptides, such as the amino acid 
sequence arginine-glycine-aspartic acid (Arg-Gly-Asp, RGD) found in many ECM 
proteins including fibronectin, laminin, vitronectin and collagen 7. The RGD modification 
alone was sufficient to transform alginate from a relative bioinert polysaccharide into a 
substrate capable of supporting endothelial cell anchorage and consequently, allowing 
cell interaction. HUVECs adhesion to the hydrogel films was possible due to the 
presence of these RGD peptides, as is shown by the limited cell adhesion and 
spreading observed on the unmodified surface (Fig. 1). The integrins that bind to the 
ECM provide not only anchorage for endothelial cells, but also information concerning 
their microenvironment, contributing to cell’s decision to proliferate, migrate or die 28. 
More precisely, the integrin αvβ3, that binds to RGD, plays an important function 
mediating cells survival and have been associated to cell migration and invasion 28, 29. 
Yu and co-workers used RGD peptides conjugated with alginate to improve heart 
functionality by regulating endothelial cell function in a chronically injured heart tissue 
29. They were able to demonstrate that this hydrogel can be used as an effective 
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acellular strategy due to the fact that integrin-ligand interaction may induce host tissue 
regeneration. Although they demonstrated an improvement in a specific disorder, for 
other situations the application of the biomaterial per se may be insufficient, and the 
co-transplantation of cells may be additionally required.  
In regenerative medicine, the use of injectable biomaterials, such as alginate 
hydrogels, with the capacity to adjust to complex shapes at the site of injury (Fig. 2) 
represents an important advantage 9. Moreover, the hydrogel network acts as an 
artificial ECM that organizes cells into an adequate 3D architecture, offering structural 
support and preserving cells phenotype and function, which may not be accomplished 
in 2D cultures. From 2D to 3D studies, a key parameter to examine was the capacity of 
alginate hydrogels to support HUVECs viability, considering that most biomaterials 
tested for that purpose poorly supported vascular cells survival 15, 27. In point of fact, in 
a prior work with 2 wt-% modified alginate, endothelial cells showed an abrupt loss of 
viability after immobilization 15. To overcome this drawback, several studies with lower 
alginate concentrations were performed until 1 wt-%. With this concentration HUVECs 
were able to maintain their viability and spread within the hydrogel matrix. As illustrated 
in Fig. 3, HUVECs retained their viability for at least 48h post-immobilization in the 
presence of RGD peptides. On the other hand, within unmodified alginate cells viability 
decreased rapidly throughout time. This phenomenon could be explained by the fact 
that endothelial cells are cell-anchorage dependent, and the lack of proper integrin-
ligand interactions, resulting from the unavailability of RGD peptides, leads to cell 
death 30. Some authors associate Ang-2 as an originator of endothelial cell apoptosis, 
or in some unfavorable circumstances (hypoxia, serum starvation, absence of 
cell/matrix interaction) capable of activating signaling pathways that promote cell 
survival 31. A higher Ang-2 expression was observed in cells immobilized within 
unmodified alginate, which could be interpreted as a sign of endothelial cells stress 
(unfavorable condition), due to the absence of cell anchorage points 32. 
A successful matrix for tissue regeneration should ideally promote the 
development of a vascular network. In the present work, the angiogenic potential of 
HUVECs immobilized within an hydrogel matrix grafted or not with RGD peptides, 
under a pro-angiogenic environment, was analyzed. HUVECs were able to organize 
into 3D cellular networks within RGD-alginate hydrogels after 24h (Fig. 4) but remained 
round and isolated within unmodified alginate. Moreover, they continued to express 
endothelial specific markers, such as vWF, a glycoprotein that mediates platelet 
adhesion at sites of vascular injury 33. The expression of this marker, which was 
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observed by confocal microscopy, indicated that HUVECs within the RGD-alginate 
matrix have been able to preserve functionality (Fig. 4D). Additionally, CFSE staining 
analyses confirmed HUVECs proliferation after 48h post-immobilization in both 
alginates, comparing to day 0 (Fig. 5). However, cells within RGD-alginate showed a 
higher rate of cell division comparing to cell within unmodified alginate. 
The dynamics of cell-ECM interactions contribute not only to cell-matrix adhesion 
but also to cell activities such as cell proliferation, invasion and migration. Cell 
migration is vital for many physiological processes including tissue vascularization. The 
injectable matrix used here for immobilizing vascular cells based on 1 wt-% modified 
alginate allowed this process, promoting a significantly higher cell migration out of the 
alginate matrix in the presence of RGD peptides (Fig. 6). In contact with a basement 
membrane extract rich in ECM proteins, only cells within RGD-alginate matrix were 
able to migrate out from the alginate in an organized way, producing several branches 
that protruded from the hydrogel matrices and invaded a Matrigel layer as tubular-like 
structures (Fig. 7). A possible explanation may rely on the higher proteolytic ability 
(expressed by higher enzymatic activity of MMP2) of cells entrapped within RGD-
alginate hydrogel, which was demonstrated by zymography. This enhanced capacity 
may assist cells in degrading the surrounding Matrigel layer, and thus facilitate ECM 
invasion by the tubular-like structures. The gelatin zymogram of the supernatants 
revealed that HUVECs in the presence of RGD, a molecular recognition motif of some 
ECM proteins, secreted higher amounts of both latent and active MMP-2, which 
increased from 24 to 48h (Fig. 8). This is in agreement with the literature, which 
demonstrated that proMMP-2 activation is modulated by the number of bindings of the 
cell surface integrin receptors to the ECM 34. In point of fact, integrin binding can 
regulate MMP activity and ECM proteolysis. Moreover, the MMP-2 activation 
represents a critical level of regulation 26, 35. 
Among the enzymes that play a critical role in extracellular matrix turnover, MMP-
2 and MMP-9 are the most important in the angiogenesis process, due to their 
collageneolytic activity that enables endothelial cells to invade the basement 
membrane of vascular structures 35. Regarding MMP-9, this enzyme also participates 
in the degradation of basement membranes, but the mechanisms that trigger its activity 
are not well understood so far. In the present study, it was not possible to detect active 
MMP-9, probably due to its low concentration in the supernatant. 
In summary, whether vascular cells are delivered from an implanted hydrogel or 
invade from the host tissues, rapid stimulation of vascular organization is critical for cell 
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survival within the implant. In this report several fundamental problems associated with 
an in situ gel forming system for vascular cells were taken into consideration – loss of 
viability, lack of vascular-like organization and absence of cell migration. The results 
obtained support the potential of using injectable alginate hydrogels as adequate 
carriers for the minimally invasive delivery of vascular cells. 
 
 
CONCLUSIONS 
 
In this work the in vitro potential of a natural hydrogel for the delivery of vascular 
cells was explored. The obtained results support the idea that an RGD-alginate matrix 
can recreate an adequate 3D microenvironment for HUVECs adhesion, survival, 
migration and 3D organization. To our knowledge, this was the first study showing the 
potential of injectable alginate hydrogels as an in situ gel forming delivery system for 
vascular cells, which supports the in vitro formation of cellular networks by migrating 
cells. 
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Bone is one of the few organs that retains the potential for regeneration in adult 
life, as it possesses the ability to heal and to remodel 1. In some clinical settings, 
however, bone is not able to heal by itself and further treatment is needed: fusion of 
bones, reconstruction of shattered bones, filling of bone defects caused by cysts or 
tumors, and stimulation of bone growth to help anchor an artificial joint or other implant 
2, 3. For most of these injuries, available treatments are still inadequate. Therefore, in 
the present thesis we propose a new strategy that might constitute a solution for some 
for some of these problems. 
The main objective of this thesis was the development of a bone tissue 
engineering strategy based on an injectable system in combination with mesenchymal 
stem cells (MSCs) and endothelial cells (ECs). The proposed system would potentially 
act as a filler to stimulate bone repair and to enhance bone function. 
Modern tissue engineering is increasingly using three-dimensional structured 
biomaterials as artificial extracellular matrices in combination with stem cells as cell 
source and/or biologically active molecules 4. A bio-inspired material was herein 
investigated, not only to serve as cell carrier by providing the adequate physical and 
mechanical support, but also to actively influence cell behavior, such as cell adhesion, 
proliferation, differentiation and function 5.  
MSCs have been widely explored for bone tissue engineering strategies due to 
their differentiation capacity into distinct end-stage cell types, their paramount role in 
endochondral and intramembranous bone formation in vivo, immunosuppressive 
properties and ability to produce a broad spectrum of bioactive macromolecules 
capable of establishing a regenerative microenvironment 6-14. 
The crosstalk between MSCs and ECs has already been identified: a paracrine 
effect mediated by vascular endothelial growth factor (VEGF), bone morphogenetic 
protein (BMP)-2 and insulin-like growth factor (IGF) production, and a juxtacrine 
mechanism by gap junctional activity (connexin 43) 15-18. Although the proficiency of 
this dialogue had been evaluated in the behavior of both cells, it has not been 
considered as a key parameter for large-scale production of MSCs. Taking into 
account that a large number of MSCs committed to the osteogenic lineage is required 
for creating a tissue-engineered implant able to fill bone defects, we investigated 
whether a coculture system of both cell types could modulate the phenotype and 
proliferation of harvested MSCs. We were able to demonstrate that, by coculturing 
MSCs with HUVECs, there was not only an enhancement of osteogenic differentiation, 
but also a significant increase on MSCs proliferation. This augmentation in cell 
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proliferation occurred independently of the relative cell ratios used, but was favored by 
higher relative amounts of HUVECs. Hence, the obtained data suggest that HUVECs 
not only modulate MSC phenotype but also their proliferation rate. Such finding, 
constituting a step forward in understanding the interaction between these two cell 
types, can easily find application in several tissue engineering approaches, where a 
high amount of cells is required and where vascularization has prime importance. 
As the field of tissue engineering progresses, improvements in the development 
of more refined and tailored cell-based therapies to replace, repair or enhance the 
function of damaged tissues or organs are emerging. The possibility of combining cells 
with biomaterials to create “living cell medicines” has open new doors. For clinical 
applications, the delivery of cells through minimally invasive approaches may be very 
attractive , since these systems offer specific advantages, such as ease of application, 
confined delivery and improved patient compliance and comfort 19.  
In the context of bone regeneration, and considering previous work from our 
group, 20, 21 it seemed relevant to us to investigate the use of alginate microspheres as 
carriers for MSCs. Calcium-crosslinked sodium alginate hydrogels present several 
advantageous features over other gel matrices used for cell immobilization, namely the 
ability to crosslink under mild conditions, to immobilize living cells and to form 3D 
constructs. In addition, they can be easily sterilized and stored, and have been 
extensively used in the form of microspheres for cell immobilization 22-26. In this work, 
alginate microspheres with an average size of 800 µm were prepared. It is worth 
mentioning that this size range was selected mainly to facilitate handling during the 
several assays performed, although these 3D matrices can be easily reduced in size 
down to 200 µm by simply varying the encapsulation settings used.  
Another parameter taken into account was the fact that alginate, although 
originally a non-cell interactive polymer, can be covalently modified with peptides 
containing the RGD sequence to promote cell adhesion 20, 27. Moreover, its molecular 
weight was modified through irradiation and oxidation to modulate its viscoelastic 
properties, as well as its degradation rate 28. The lower viscosity of the irradiated 
polymer results in reduced shear forces during the cell-polymer mixing process and, 
consequently, in higher cell viability 29. Previous studies using RGD-alginate 
microspheres with a binary composition of high and low molecular weight alginate 
already demonstrated the usefulness of this 3D system for the immobilization of 
MC3T3-E1 osteoblast-like cells 20, 21. As highlighted above, MSCs represent a more 
clinically relevant cell source. Accordingly, we characterized in detail the viability, 
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metabolic activity and osteogenic potential of MSCs immobilized within RGD-alginate 
microspheres cultured under basal and osteogenic induction conditions. We were able 
to demonstrate that MSCs could be entrapped in RGD-alginate maintaining a high 
viability, and be kept metabolically active during 3 weeks under 3D culture. Moreover, 
MSCs immobilized in this 3D alginate matrix were also able to respond to 
environmental biochemical cues from the media by differentiating into osteoblasts 
when cultured in osteogenic media. 
It is now widely accepted that the success of a bone tissue engineering implant 
largely relies on its capacity to influence the surrounding environment and, eventually, 
on triggering new vessel formation. For that reason, we also studied the ability of a 
MSCs-alginate 3D construct to enhance the sprouting of vessels by neighboring 
endothelial cells. By applying a well-known methodology, the Matrigel assay, we 
observed that MSCs immobilized inside RGD-grafted alginate microspheres 
significantly enhanced the ability of neighboring endothelial cells to form tube-like 
structures. In addition, the presence of VEGF was monitored in the culture medium, 
showing not only that hMSC were able to produce this signaling protein, but also that it 
was able to diffuse through the hydrogel network into the surrounding medium.  
In future works, the in vivo performance of MSCs-loaded microspheres upon 
implantation on critically sized bone-defects created in suitable animal models would 
provide further insights into the usefulness of this system under physiological 
conditions. Nevertheless, to be applied via minimally invasive surgical strategies (for 
instance, through injection), the system described above would require a vehicle with in 
situ gel-forming ability to deliver the MSC-loaded microspheres into the defect and to 
keep them in place. Some hydrogel matrices, like alginate, can be prepared from 
soluble precursor solutions that crosslink in situ, which would allow the application of 
the microspheres at the injury site by minimally invasive methods 30, 31. As a future 
perspective, the injectability of these microspheres deserves investigation. An ideal 
vehicle, with adequate rheological properties allowing the implantation of microspheres 
through a minimally invasive approach, needs to be developed. Although alginate 
stands up as a good candidate, a meticulous study must be carried out. 
Of vital importance to a good performance of a biomaterial scaffold is its capacity 
to allow the proper vascularization, and therefore, vascular cell survival and 
organization. In our experimental conditions, immobilized MSCs were able to stimulate 
ECs in a reconstituted basement membrane (Matrigel). The next step consisted in 
evaluating the survival of ECs within the alginate matrix, which was proven to be low. 
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In point of fact, in a prior work with 2 wt-% modified alginate, endothelial cells showed 
an abrupt loss of viability after immobilization 21. To overcome this drawback, several 
studies with lower alginate concentrations were performed until 1 wt-%. Using this 
concentration we were able to develop a hydrogel matrix where ECs retained their 
viability at least 48h post-immobilization. Moreover, such cells spread, formed a cellular 
network and were able to migrate out from the alginate hydrogels. In light of a clinical 
application, the vascular cell source needs to be carefully addressed. Although in this 
work we used a very well characterized endothelial cell line to demonstrate the alginate 
potential, from a clinical perspective, mature ECs present some disadvantages, such 
as reduced availability and proliferation rate. As an alternative, autologous cells like 
outgrowth endothelial cells (a subpopulation of endothelial progenitor cells) appear as 
a powerful candidate for regenerative medicine, as more knowledge about their 
biological properties is being revealed 32-38. In spite of some controversy, these cells 
have been successfully applied in 3D matrices and there is no doubt regarding their 
ability to enhance angiogenesis and vascular repair 37, 39-42. Although ECs have an 
inherent capacity to form tubular structures, the formation of long-lasting vessels within 
a 3D matrix using a coculture system with pericytes or smooth muscle cells should be 
evaluated as well 11, 43, 44. 
Overall, we were able to demonstrate that MSCs could be expanded ex vivo in 
the presence of ECs and further delivered in a RGD-modified alginate. Finally, we 
studied the potential of this biomaterial-based system as an in situ gel forming delivery 
system able to promote the outward migration of viable, functional and proliferative 
endothelial cells. As future perspectives, although RGD-modified alginate successfully 
immobilized MSCs and ECs, further modifications should be considered to improve the 
3D alginate microenvironment. For instance, modification of alginate with a protease-
labile double-end grafted crosslinking peptide, cleavable by matrix metalloproteinases, 
would provide a more dynamic 3D environment, allowing cells to remodel the matrix 
and create pathways 31. 
The development of a potential injectable system, able to simultaneously provide 
a source of viable bone and vascular cells and to stimulate an angiogenesis-like 
response in the host, may represent a breakthrough in bone regeneration strategies.  
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